Literatur

NVL Chronische KHK

4. Auflage, 2016. Version 1 – Druckversion (PDF ) | Kapitelübersicht | weitere Informationen

1. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische KHK - Langfassung, 3. Auflage. Version 1. 2014 [cited: 2014 Dez 16]. Available from: http://doi.org/10.6101/AZQ/000217, DOI: 10.6101/AZQ/000217

2. Europarat, Verbindung der Schweizer Ärztinnen und Ärzte, Ärztliche Zentralstelle Qualitätssicherung (ÄZQ), et al. Entwicklung einer Methodik für die Ausarbeitung von Leitlinien für optimale medizinische Praxis. Empfehlung Rec (2001)13 des Europarates am 10. Oktober 2001 und Erläuterndes Memorandum. Deutschsprachige Ausgabe. Z Arztl Fortbild Qualitatssich 2002;96(Suppl III):3-60 http://www.leitlinien.de/mdb/edocs/pdf/literatur/europaratmethdt.pdf.

3. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV). Beurteilungskriterien für Leitlinien in der medizinischen Versorgung - Beschlüsse der Vorstände der Bundesärztekammer und Kassenärztlicher Bundesvereinigung, Juni 1997. Dtsch Arztebl 1997;94(33):A-2154-5.

4. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Ärztliche Zentralstelle Qualitätssicherung (ÄZQ). Das Leitlinien-Manual von AWMF und ÄZQ. Entwicklung und Implementierung von Leitlinien in der Medizin. Z Arztl Fortbild Qualitatssich 2001;95(Suppl I):4-84.

5. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Das AWMF-Regelwerk Leitlinien. München: Zuckschwerdt; 2012 Available from: http://www.awmf.org/leitlinien/awmf-regelwerk.html.

6. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV). Das Leitlinien-Clearingverfahren von Bundesärztekammer und Kassenärztlicher Bundesvereinigung in Zusammenarbeit mit der Deutschen Krankenhausgesellschaft und den Spitzenverbänden der Gesetzlichen Krankenversicherungen, Ziele und Arbeitsplan. Dtsch Arztebl 1999;96(33):A-2105-6.

7. Ärztliches Zentrum für Qualität in der Medizin (ÄZQ). Das Deutsche Leitlinien-Clearingverfahren 1999-2005. Hintergrund, Zielsetzung, Ergebnisse. Abschlussbericht. Leitlinien-Clearingverfahren von Bundesärztekammer und Kassenärztlicher Bundesvereinigung in Kooperation mit Deutscher Krankenhausgesellschaft, Spitzenverbände der Krankenversicherungen und Gesetzlicher Rentenversicherung. Norderstedt: BoD, Books on Demand; 2006 (äzq Schriftenreihe; 24). Available from: http://www.leitlinien.de/leitlinienmethodik/clearingverfahren.

8. Ärztliches Zentrum für Qualität in der Medizin (ÄZQ), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Deutsches Instrument zur methodischen Leitlinien-Bewertung (DELBI). Fassung 2005/2006. Z Arztl Fortbild Qualitatssich 2005;99(8):468-519.

9. Ärztliches Zentrum für Qualität in der Medizin (ÄZQ), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Deutsches Instrument zur methodischen Leitlinien-Bewertung (DELBI). Fassung 2005/2006 + Domäne 8. 2008 [cited: 2016 Jan 04]. Available from: http://www.leitlinien.de/mdb/edocs/pdf/literatur/
delbi-fassung-2005-2006-domaene-8-2008.pdf

10. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationales Programm für VersorgungsLeitlinien. Methoden-Report 4. Auflage. 2010 [cited: 2015 Sep 15]. Available from: http://www.leitlinien.de/mdb/downloads/nvl/methodik/mr-aufl-4-version-1.pdf, DOI: 10.6101/AZQ/000061

11. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische KHK. Leitlinien-Report. Version 5. 2006 [cited: 2014 Sep 09]. Available from: http://doi.org/10.6101/AZQ/000221, DOI: 10.6101/AZQ/000221

12. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische KHK zur 2. Auflage, Kapitel 11 "Medikamentöse Therapie". Leitlinien-Report. Version 2. 2012 [cited: 2014 Sep 09]. Available from: http://www.khk.versorgungsleitlinien.de, DOI: 10.6101/AZQ/000062

13. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische KHK zur 3. Auflage, Kapitel 12 „Revaskularisationstherapie". Leitlinien-Report. Version 1. 2014 [cited: 2014 Dez 18]. Available from: http://doi.org/10.6101/AZQ/000216, DOI: 10.6101/AZQ/000216

14. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001;323(7308):334-6 http://www.ncbi.nlm.nih.gov/pubmed/11498496.

15. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490-7 http://www.ncbi.nlm.nih.gov/pubmed/15205295.

16. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6 http://www.ncbi.nlm.nih.gov/pubmed/18436948.

17. Ärztliches Zentrum für Qualität in der Medizin (ÄZQ). Leitlinien-Clearingbericht "Koronare Herzkrankheit". Niebüll: videel; 2003 (äzq Schriftenreihe; 11). Available from: http://www.leitlinien.de/leitlinienmethodik/clearingverfahren/
clearingberichte/leitlinien-clearingverfahren-koronare-herzkrankheit
.

18. Deutsche Gesellschaft für Kardiologie (DGK), Zeymer U, Kastrati A, et al. ESC Pocket Guidelines. Therapie des akuten Herzinfarktes bei Patienten mit persistierender ST-Streckenhebung. Update 2012. 2012 [cited: 2015 Jun 09]. Available from: http://leitlinien.dgk.org/files/PL_STEMI_Internet_13.pdf

19. Deutsche Gesellschaft für Kardiologie (DGK). Infarkt-bedingter kardiogener Schock - Diagnose, Monitoring und Therapie. Langfassung. 2010 [cited: 2015 Jan 13]. Available from: http://www.awmf.org/uploads/tx_szleitlinien/019-013_S3_
Infarkt-bedingter_kardiogener_Schock_-_Diagnose__Monitoring_und_Therapie_lang_05-2010_05-2015.pdf

20. Deutsche Gesellschaft für Kardiologie (DGK), Achenbach S, Hamm CW. ESC Pocket Guidelines. Akutes Koronarsyndrom ohne ST-Hebung (NSTE-ACS). Update 2011. 2012 [cited: 2015 Jun 09]. Available from: http://leitlinien.dgk.org/files
/2012_Pocket-Leitlinie_Akutes_Koronarsyndrom_NSTE-ACS.pdf

21. European Society of Cardiology (ESC), Hamm CW, Bassand JP, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32(23):2999-3054 http://www.ncbi.nlm.nih.gov/pubmed/21873419, DOI: 10.1093/eurheartj/ehr236.

22. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33(20):2569-619 http://www.ncbi.nlm.nih.gov/pubmed/22922416, DOI: 10.1093/eurheartj/ehs215.

23. Scottish Intercollegiate Guidelines Network (SIGN). Acute coronary syndromes. A national clinical guideline. Updated February 2013. Edinburgh: SIGN; 2013 (SIGN Publications; 93). Available from: http://www.sign.ac.uk/pdf/sign93.pdf.

24. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;130(25):e344-e426 http://www.ncbi.nlm.nih.gov/pubmed/25249585, DOI: 10.1161/CIR.0000000000000134.

25. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127(4):e362-e425 http://www.ncbi.nlm.nih.gov/pubmed/23247304, DOI: 10.1161/CIR.0b013e3182742cf6.

26. Gesundheitsberichterstattung des Bundes (GBE). Statistik der häufigsten Todesursachen 2003-2013. Abgerufen am 24.03.2015. 2015 [cited: 2015 Mae 30]. Available from: http://www.gbe-bund.de

27. Gosswald A, Schienkiewitz A, Nowossadeck E, et al. Prävalenz von Herzinfarkt und koronarer Herzkrankheit bei Erwachsenen im Alter von 40 bis 79 Jahren in Deutschland. Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013;56(5-6):650-5 http://www.ncbi.nlm.nih.gov/pubmed/23703482, DOI: 10.1007/s00103-013-1666-9.

28. Canadian Cardiovascular Society (CCS). Grading of angina. 1976 [cited: 2014 Sep 09]. Available from: http://ccs.ca/images/Guidelines/PositionStatements/Grading_of_Angina.pdf

29. Weber M, Hamm C. Die instabile Angina pectoris (IAP) nach neuer Klassifikation. Welche Diagnostik--welche Therapie? Dtsch Med Wochenschr 2004;129(19):1082-8 http://www.ncbi.nlm.nih.gov/pubmed/15136954.

30. Daly CA, de Stavola B, Sendon JL, et al. Predicting prognosis in stable angina--results from the Euro heart survey of stable angina: prospective observational study. BMJ 2006;332(7536):262-7 http://www.ncbi.nlm.nih.gov/pubmed/16415069.

31. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34(38):2949-3003 http://www.ncbi.nlm.nih.gov/pubmed/23996286, DOI: 10.1093/eurheartj/eht296.

32. Verdon F, Herzig L, Burnand B, et al. Chest pain in daily practice: occurrence, causes and management. Swiss Med Wkly 2008;138(23-24):340-7 http://www.ncbi.nlm.nih.gov/pubmed/18561039.

33. Bosner S, Becker A, Haasenritter J, et al. Chest pain in primary care: epidemiology and pre-work-up probabilities. Eur J Gen Pract 2009;15(3):141-6 http://www.ncbi.nlm.nih.gov/pubmed/19883149, DOI: 10.3109/13814780903329528.

34. Haasenritter J, Bosner S, Vaucher P, et al. Ruling out coronary heart disease in primary care: external validation of a clinical prediction rule. Br J Gen Pract 2012;62(599):e415-e421 http://www.ncbi.nlm.nih.gov/pubmed/22687234, DOI: 10.3399/bjgp12X649106.

35. Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM), Haasenritter J, Bösner S, et al. Brustschmerz. DEGAM-Leitlinie Nr. 15. Düsseldorf: Omikron Publ.; 2011 Available from: http://www.degam.de/files/Inhalte/Leitlinien-Inhalte/
Dokumente/DEGAM-S3-Leitlinien/LL-15_Langfassung_Brustschmerz.pdf
.

36. Cooper A, Calvert N, Skinner J, et al. Chest pain of recent onset: Assessment and diagnosis of recent onset chest pain or discomfort of suspected cardiac origin. London: National Clinical Guideline Centre for Acute and Chronic Conditions; 2010 Available from: http://www.nice.org.uk/nicemedia/live/12947/47931/47931.pdf.

37. Bösner S, Becker A, Abu HM, et al. Accuracy of symptoms and signs for coronary heart disease assessed in primary care. Br J Gen Pract 2010;60(575):e246-e257 http://www.ncbi.nlm.nih.gov/pubmed/20529488.

38. Gencer B, Vaucher P, Herzig L, et al. Ruling out coronary heart disease in primary care patients with chest pain: a clinical prediction score. BMC Med 2010;8:9 http://www.ncbi.nlm.nih.gov/pubmed/20092615.

39. Herrmann-Lingen C, Buss U. Angst und Depressivität im Verlauf der koronaren Herzkrankheit. Frankfurt/Main: VAS; 2002 (Statuskonferenz Psychokardiologie; 5). Available from: http://www.vasverlag.de/product_info.php?info=p231_Angst-
und-Depressivitaet-im-Verlauf-der-koronaren-Herzkrankheit---Christoph-Herrmann-
Lingen---Ullrich-Buss.html&XTCsid=0437b90aa1a4e4882078a99ccbb9939d
.

40. Bosner S, Haasenritter J, Becker A, et al. Ruling out coronary artery disease in primary care: development and validation of a simple prediction rule. CMAJ 2010;182(12):1295-300 http://www.ncbi.nlm.nih.gov/pubmed/20603345.

41. Genders TS, Steyerberg EW, Alkadhi H, et al. A clinical prediction rule for the diagnosis of coronary artery disease: validation, updating, and extension. Eur Heart J 2011;32(11):1316-30 http://www.ncbi.nlm.nih.gov/pubmed/21367834, DOI: 10.1093/eurheartj/ehr014.

42. Diamond GA, Staniloff HM, Forrester JS, et al. Computer-assisted diagnosis in the noninvasive evaluation of patients with suspected coronary artery disease. J Am Coll Cardiol 1983;1(2 Pt 1):444-55 http://www.ncbi.nlm.nih.gov/pubmed/6338081.

43. American College of Cardiology Foundation, American College of Radiology, Society of Cardiovascular Computed Tomography (SCCT), et al. ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging. J Am Coll Cardiol 2006;48(7):1475-97 http://www.ncbi.nlm.nih.gov/pubmed/17010819, DOI: 10.1016/j.jacc.2006.07.003.

44. Skinner JS, Smeeth L, Kendall JM, et al. NICE guidance. Chest pain of recent onset: assessment and diagnosis of recent onset chest pain or discomfort of suspected cardiac origin. Heart 2010;96(12):974-8 http://www.ncbi.nlm.nih.gov/pubmed/20538674, DOI: 10.1136/hrt.2009.190066.

45. Chun AA, McGee SR. Bedside diagnosis of coronary artery disease: a systematic review. Am J Med 2004;117(5):334-43 http://www.ncbi.nlm.nih.gov/pubmed/15336583, DOI: 10.1016/j.amjmed.2004.03.021.

46. Mant J, McManus RJ, Oakes RA, et al. Systematic review and modelling of the investigation of acute and chronic chest pain presenting in primary care. Health Technol Assess 2004;8(2):iii1-iii158 http://www.ncbi.nlm.nih.gov/pubmed/14754562.

47. Cheitlin MD, Alpert JS, Armstrong WF, et al. ACC/AHA Guidelines for the Clinical Application of Echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in colloboration with the American Society of Echocardiography. Circulation 1997;95(6):1686-744 http://www.ncbi.nlm.nih.gov/pubmed/9118558.

48. Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Soc Echocardiogr 2003;16(10):1091-110 http://www.ncbi.nlm.nih.gov/pubmed/14566308.

49. American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography (ASE), American Society of Nuclear Cardiology (ASNC), et al. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. Journal of the American College of Cardiology 2011;57(9):1126-66 http://www.ncbi.nlm.nih.gov/pubmed/21349406, DOI: 10.1016/j.jacc.2010.11.002.

50. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz. 2009 [cited: 2010 Aug 23]. Available from: http://www.versorgungsleitlinien.de/themen/herzinsuffizienz

51. Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28(20):2539-50 http://www.ncbi.nlm.nih.gov/pubmed/17428822, DOI: 10.1093/eurheartj/ehm037.

52. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009;10(2):165-93 http://www.ncbi.nlm.nih.gov/pubmed/19270053, DOI: 10.1093/ejechocard/jep007.

53. Redfield MM, Jacobsen SJ, Burnett JC, Jr., et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003;289(2):194-202 http://www.ncbi.nlm.nih.gov/pubmed/12517230.

54. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010;23(7):685-713 http://www.ncbi.nlm.nih.gov/pubmed/20620859, DOI: 10.1016/j.echo.2010.05.010.

55. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34(28):2159-219 http://www.ncbi.nlm.nih.gov/pubmed/23771844, DOI: 10.1093/eurheartj/eht151.

56. Snow V, Barry P, Fihn SD, et al. Evaluation of primary care patients with chronic stable angina: guidelines from the American College of Physicians. Ann Intern Med 2004;141(1):57-64 http://www.ncbi.nlm.nih.gov/pubmed/15238371.

57. Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr 2009;22(1):1-23 http://www.ncbi.nlm.nih.gov/pubmed/19130998, DOI: 10.1016/j.echo.2008.11.029.

58. Lancellotti P, Moura L, Pierard LA, et al. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease). Eur J Echocardiogr 2010;11(4):307-32 http://www.ncbi.nlm.nih.gov/pubmed/20435783, DOI: 10.1093/ejechocard/jeq031.

59. Visser CA, Kan G, David GK, et al. Echocardiographic-cineangiographic correlation in detecting left ventricular aneurysm: a prospective study of 422 patients. Am J Cardiol 1982;50(2):337-41 http://www.ncbi.nlm.nih.gov/pubmed/7102561.

60. de Jong MC, Genders TS, van Geuns RJ, et al. Diagnostic performance of stress myocardial perfusion imaging for coronary artery disease: a systematic review and meta-analysis. Eur Radiol 2012; http://www.ncbi.nlm.nih.gov/pubmed/22527375, DOI: 10.1007/s00330-012-2434-1.

61. Chen L, Wang X, Bao J, et al. Direct comparison of cardiovascular magnetic resonance and single-photon emission computed tomography for detection of coronary artery disease: a meta-analysis. PLoS One 2014;9(2):e88402 http://www.ncbi.nlm.nih.gov/pubmed/24520382, DOI: 10.1371/journal.pone.0088402.

62. Parker MW, Iskandar A, Limone B, et al. Diagnostic accuracy of cardiac positron emission tomography versus single photon emission computed tomography for coronary artery disease: a bivariate meta-analysis. Circ Cardiovasc Imaging 2012;5(6):700-7 http://www.ncbi.nlm.nih.gov/pubmed/23051888, DOI: 10.1161/CIRCIMAGING.112.978270.

63. Nandalur KR, Dwamena BA, Choudhri AF, et al. Diagnostic performance of stress cardiac magnetic resonance imaging in the detection of coronary artery disease: a meta-analysis. Journal of the American College of Cardiology 2007;50(14):1343-53 http://www.ncbi.nlm.nih.gov/pubmed/17903634.

64. Li S, Ni Q, Wu H, et al. Diagnostic accuracy of 320-slice computed tomography angiography for detection of coronary artery stenosis: meta-analysis. Int J Cardiol 2013;168(3):2699-705 http://www.ncbi.nlm.nih.gov/pubmed/23566493, DOI: 10.1016/j.ijcard.2013.03.023.

65. Powell H, Cosson P. Comparison of 64-slice computed tomography angiography and coronary angiography for the detection and assessment of coronary artery disease in patients with angina: a systematic review. Radiogr 2013;19(2):168-75, DOI: 10.1016/j.radi.2012.12.005.

66. Gorenoi V, Schonermark MP, Hagen A. CT coronary angiography vs. invasive coronary angiography in CHD. GMS Health Technol Assess 2012;8:Doc02 http://www.ncbi.nlm.nih.gov/pubmed/22536300, DOI: 10.3205/hta000100.

67. Nielsen LH, Ortner N, Norgaard BL, et al. The diagnostic accuracy and outcomes after coronary computed tomography angiography vs. conventional functional testing in patients with stable angina pectoris: a systematic review and meta-analysis. Eur Heart J Cardiovasc Imaging 2014; http://www.ncbi.nlm.nih.gov/pubmed/24618659, DOI: 10.1093/ehjci/jeu027.

68. Banerjee A, Newman DR, Van den Bruel A, et al. Diagnostic accuracy of exercise stress testing for coronary artery disease: a systematic review and meta-analysis of prospective studies. Int J Clin Pract 2012;66(5):477-92 http://www.ncbi.nlm.nih.gov/pubmed/22512607, DOI: 10.1111/j.1742-1241.2012.02900.x.

69. Knuuti J, Bengel F, Bax JJ, et al. Risks and benefits of cardiac imaging: an analysis of risks related to imaging for coronary artery disease. Eur Heart J 2014;35(10):633-8 http://www.ncbi.nlm.nih.gov/pubmed/24375074, DOI: 10.1093/eurheartj/eht512.

70. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol 2002;40(8):1531-40 http://www.ncbi.nlm.nih.gov/pubmed/12392846.

71. Trappe HJ, Lollgen H. Leitlinien zur Ergometrie. Z Kardiol 2000;89(9):821-31 http://www.ncbi.nlm.nih.gov/pubmed/11077695.

72. Lee TH, Boucher CA. Clinical practice. Noninvasive tests in patients with stable coronary artery disease. N Engl J Med 2001;344(24):1840-5 http://www.ncbi.nlm.nih.gov/pubmed/11407346.

73. Gianrossi R, Detrano R, Mulvihill D, et al. Exercise-induced ST depression in the diagnosis of coronary artery disease. A meta-analysis. Circulation 1989;80(1):87-98 http://www.ncbi.nlm.nih.gov/pubmed/2661056.

74. Kwok Y, Kim C, Grady D, et al. Meta-analysis of exercise testing to detect coronary artery disease in women. Am J Cardiol 1999;83(5):660-6 http://www.ncbi.nlm.nih.gov/pubmed/10080415.

75. Sicari R, Nihoyannopoulos P, Evangelista A, et al. Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur J Echocardiogr 2008;9(4):415-37 http://www.ncbi.nlm.nih.gov/pubmed/18579481, DOI: 10.1093/ejechocard/jen175.

76. Pellikka PA, Nagueh SF, Elhendy AA, et al. American Society of Echocardiography recommendations for performance, interpretation, and application of stress echocardiography. J Am Soc Echocardiogr 2007;20(9):1021-41 http://www.ncbi.nlm.nih.gov/pubmed/17765820, DOI: 10.1016/j.echo.2007.07.003.

77. Metz LD, Beattie M, Hom R, et al. The prognostic value of normal exercise myocardial perfusion imaging and exercise echocardiography: a meta-analysis. J Am Coll Cardiol 2007;49(2):227-37 http://www.ncbi.nlm.nih.gov/pubmed/17222734, DOI: 10.1016/j.jacc.2006.08.048.

78. Deutsche Gesellschaft für Nuklearmedizin (DGN), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Bengel F, et al. Myokard-Perfusions-Szintigraphie. 2012 [cited: 2015 Jan 06]. Available from: http://www.awmf.org/
uploads/tx_szleitlinien/031-006l_S1_Myokard_Perfusions-Szintigraphie_2012-05_01.pdf

79. Zhou T, Yang LF, Zhai JL, et al. SPECT myocardial perfusion versus fractional flow reserve for evaluation of functional ischemia: a meta analysis. Eur J Radiol 2014;83(6):951-6 http://www.ncbi.nlm.nih.gov/pubmed/24666512, DOI: 10.1016/j.ejrad.2014.02.018.

80. Kramer CM, Barkhausen J, Flamm SD, et al. Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. J Cardiovasc Magn Reson 2013;15:91 http://www.ncbi.nlm.nih.gov/pubmed/24103764, DOI: 10.1186/1532-429X-15-91.

81. Desai RR, Jha S. Diagnostic performance of cardiac stress perfusion MRI in the detection of coronary artery disease using fractional flow reserve as the reference standard: a meta-analysis. AJR Am J Roentgenol 2013;201(2):W245-W252 http://www.ncbi.nlm.nih.gov/pubmed/23883239, DOI: 10.2214/AJR.12.10002.

82. Iwata K, Nakagawa S, Ogasawara K. The prognostic value of normal stress cardiovascular magnetic resonance imaging. J Comput Assist Tomogr 2014;38(1):36-43 http://www.ncbi.nlm.nih.gov/pubmed/24424555, DOI: 10.1097/RCT.0b013e3182a474a0.

83. Achenbach S, Barkhausen J, Beer M, et al. Konsensusempfehlungen der DRG/DGK/DGPK zum Einsatz der Herzbildgebung mit Computertomografie und Magnetresonanztomografie. Rofo 2012;184(4):345-68 http://www.ncbi.nlm.nih.gov/pubmed/22426867.

84. Abbara S, Arbab-Zadeh A, Callister TQ, et al. SCCT guidelines for performance of coronary computed tomographic angiography: a report of the Society of Cardiovascular Computed Tomography Guidelines Committee. J Cardiovasc Comput Tomogr 2009;3(3):190-204 http://www.ncbi.nlm.nih.gov/pubmed/19409872, DOI: 10.1016/j.jcct.2009.03.004.

85. Halliburton SS, Abbara S, Chen MY, et al. SCCT guidelines on radiation dose and dose-optimization strategies in cardiovascular CT. J Cardiovasc Comput Tomogr 2011;5(4):198-224 http://www.ncbi.nlm.nih.gov/pubmed/21723512, DOI: 10.1016/j.jcct.2011.06.001.

86. von Ballmoos MW, Haring B, Juillerat P, et al. Meta-analysis: diagnostic performance of low-radiation-dose coronary computed tomography angiography. Ann Intern Med 2011;154(6):413-20 http://www.ncbi.nlm.nih.gov/pubmed/21403076, DOI: 10.1059/0003-4819-154-6-201103150-00007.

87. Sarno G, Decraemer I, Vanhoenacker PK, et al. On the inappropriateness of noninvasive multidetector computed tomography coronary angiography to trigger coronary revascularization: a comparison with invasive angiography. JACC Cardiovasc Interv 2009;2(6):550-7 http://www.ncbi.nlm.nih.gov/pubmed/19539260, DOI: 10.1016/j.jcin.2009.03.009.

88. Habib PJ, Green J, Butterfield RC, et al. Association of cardiac events with coronary artery disease detected by 64-slice or greater coronary CT angiography: A systematic review and meta-analysis. Int J Cardiol 2013;169(2):112-20 http://www.ncbi.nlm.nih.gov/pubmed/24090745, DOI: 10.1016/j.ijcard.2013.08.096.

89. Bundesamt für Strahlenschutz (BfS). Bundesamt für Strahlenschutz: Bekanntmachung der aktualisierten diagnostischen Referenzwerte für diagnostische und interventionelle Röntgenuntersuchungen. 2010 [cited: 2015 Juli 06]. Available from: http://www.bfs.de/SharedDocs/Downloads/BfS/DE/fachinfo/ion/drw-roentgen.pdf?__blob=publicationFile&v=1

90. Bundesamt für Strahlenschutz (BfS). Bundesamt für Strahlenschutz: Bekanntmachung der aktualisierten diagnostischen Referenzwerte für nuklearmedizinische Untersuchungen. 2012 [cited: 2015 Juli 06]. Available from: http://www.laekb.de/
files/1456FC3088F/Referenzwerte_Nuklearmedizin.pdf

91. Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2014;130(19):1749-67 http://www.ncbi.nlm.nih.gov/pubmed/25070666, DOI: 10.1161/CIR.0000000000000095.

92. National Institute for Health and Clinical Excellence (NICE). Management of stable angina. Last modified: December 2012. London: NICE; 2011 (NICE Clinical Guideline; 126). Available from: http://www.nice.org.uk/guidance/cg126/
resources/guidance-management-of-stable-angina-pdf
.

93. Lichtman JH, Froelicher ES, Blumenthal JA, et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation 2014;129(12):1350-69 http://www.ncbi.nlm.nih.gov/pubmed/24566200, DOI: 10.1161/CIR.0000000000000019.

94. Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J 2006;27(23):2763-74 http://www.ncbi.nlm.nih.gov/pubmed/17082208, DOI: 10.1093/eurheartj/ehl338.

95. Rutledge T, Redwine LS, Linke SE, et al. A meta-analysis of mental health treatments and cardiac rehabilitation for improving clinical outcomes and depression among patients with coronary heart disease. Psychosom Med 2013;75(4):335-49 http://www.ncbi.nlm.nih.gov/pubmed/23630306, DOI: 10.1097/PSY.0b013e318291d798.

96. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN), Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), et al. S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression - Langfassung, 2. Auflage. Version 2. 2015 [cited: 2015 Dez 18]. Available from: http://doi.org/10.6101/AZQ/000266, DOI: 10.6101/AZQ/000266

97. Tonne C, Schwartz J, Mittleman M, et al. Long-term survival after acute myocardial infarction is lower in more deprived neighborhoods. Circulation 2005;111(23):3063-70 http://www.ncbi.nlm.nih.gov/pubmed/15939820, DOI: 10.1161/CIRCULATIONAHA.104.496174.

98. Stringhini S, Sabia S, Shipley M, et al. Association of socioeconomic position with health behaviors and mortality. JAMA 2010;303(12):1159-66 http://www.ncbi.nlm.nih.gov/pubmed/20332401, DOI: 10.1001/jama.2010.297.

99. Alter DA, Franklin B, Ko DT, et al. Socioeconomic status, functional recovery, and long-term mortality among patients surviving acute myocardial infarction. PLoS One 2014;8(6):e65130 http://www.ncbi.nlm.nih.gov/pubmed/23755180, DOI: 10.1371/journal.pone.0065130.

100. Barth J, Schneider S, von KR. Lack of social support in the etiology and the prognosis of coronary heart disease: a systematic review and meta-analysis. Psychosom Med 2010;72(3):229-38 http://www.ncbi.nlm.nih.gov/pubmed/20223926, DOI: 10.1097/PSY.0b013e3181d01611.

101. Richardson S, Shaffer JA, Falzon L, et al. Meta-analysis of perceived stress and its association with incident coronary heart disease. Am J Cardiol 2012;110(12):1711-6 http://www.ncbi.nlm.nih.gov/pubmed/22975465, DOI: 10.1016/j.amjcard.2012.08.004.

102. Virtanen M, Ferrie JE, Singh-Manoux A, et al. Overtime work and incident coronary heart disease: the Whitehall II prospective cohort study. Eur Heart J 2010;31(14):1737-44 http://www.ncbi.nlm.nih.gov/pubmed/20460389, DOI: 10.1093/eurheartj/ehq124.

103. Eller NH, Netterstrom B, Gyntelberg F, et al. Work-related psychosocial factors and the development of ischemic heart disease: a systematic review. Cardiol Rev 2009;17(2):83-97 http://www.ncbi.nlm.nih.gov/pubmed/19367150, DOI: 10.1097/CRD.0b013e318198c8e9.

104. Orth-Gomer K, Wamala SP, Horsten M, et al. Marital stress worsens prognosis in women with coronary heart disease: The Stockholm Female Coronary Risk Study. JAMA 2000;284(23):3008-14 http://www.ncbi.nlm.nih.gov/pubmed/11122587.

105. Roest AM, Martens EJ, de JP, et al. Anxiety and risk of incident coronary heart disease: a meta-analysis. Journal of the American College of Cardiology 2010;56(1):38-46 http://www.ncbi.nlm.nih.gov/pubmed/20620715, DOI: 10.1016/j.jacc.2010.03.034.

106. Roest AM, Martens EJ, Denollet J, et al. Prognostic association of anxiety post myocardial infarction with mortality and new cardiac events: a meta-analysis. Psychosom Med 2010;72(6):563-9 http://www.ncbi.nlm.nih.gov/pubmed/20410247, DOI: 10.1097/PSY.0b013e3181dbff97.

107. Edmondson D, Kronish IM, Shaffer JA, et al. Posttraumatic stress disorder and risk for coronary heart disease: a meta-analytic review. Am Heart J 2013;166(5):806-14 http://www.ncbi.nlm.nih.gov/pubmed/24176435, DOI: 10.1016/j.ahj.2013.07.031.

108. Edmondson D, Richardson S, Falzon L, et al. Posttraumatic stress disorder prevalence and risk of recurrence in acute coronary syndrome patients: a meta-analytic review. PLoS One 2012;7(6):e38915 http://www.ncbi.nlm.nih.gov/pubmed/22745687, DOI: 10.1371/journal.pone.0038915.

109. Fan Z, Wu Y, Shen J, et al. Schizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies. J Psychiatr Res 2013;47(11):1549-56 http://www.ncbi.nlm.nih.gov/pubmed/23953755, DOI: 10.1016/j.jpsychires.2013.07.011.

110. Walker ER, McGee RE, Druss BG. Mortality in Mental Disorders and Global Disease Burden Implications: A Systematic Review and Meta-analysis. JAMA Psychiatry 2015;72(4):334-41 http://www.ncbi.nlm.nih.gov/pubmed/25671328, DOI: 10.1001/jamapsychiatry.2014.2502.

111. Chida Y, Steptoe A. The association of anger and hostility with future coronary heart disease: a meta-analytic review of prospective evidence. Journal of the American College of Cardiology 2009;53(11):936-46 http://www.ncbi.nlm.nih.gov/pubmed/19281923, DOI: 10.1016/j.jacc.2008.11.044.

112. Grande G, Romppel M, Barth J. Association between type D personality and prognosis in patients with cardiovascular diseases: a systematic review and meta-analysis. Ann Behav Med 2012;43(3):299-310 http://www.ncbi.nlm.nih.gov/pubmed/22237826, DOI: 10.1007/s12160-011-9339-0.

113. Bandelow B, Wiltink J, Alpers GW, et al. S3-Leitlinie Behandlung von Angststörungen. Kurzversion. 2014 [cited: 2015 Feb 26]. Available from: http://www.awmf.org/uploads/tx_szleitlinien/051-028k_S3_Angstst%C3%B6rungen_2014-05_1.pdf

114. Deutschsprachige Gesellschaft für Psychotraumatologie (DeGPT), Deutsche Gesellschaft für Psychotherapeutische Medizin und ärztliche Psychotherapie (DGPM), Deutsches Kollegium für Psychosomatische Medizin (DKPM), et al. S3-Leitlinie. Posttraumatische Belastungsstörung. ICD 10: F 43.1. 2011 [cited: 2015 Mar 02]. Available from: http://www.awmf.org/uploads/tx_szleitlinien/051-010l_S3_Posttraumatische_Belastungsstoerung_2012-03.pdf

115. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN). Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff; 2006 (S3 Praxisleitlinien in Psychiatrie und Psychotherapie; 1).

116. Perk J, De BG, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2012;33(13):1635-701 http://www.ncbi.nlm.nih.gov/pubmed/22555213, DOI: 10.1093/eurheartj/ehs092.

117. Ladwig KH, Lederbogen F, Albus C, et al. Positionspapier zur Bedeutung psychosozialer Faktoren in der Kardiologie. Update 2013. Kardiologe 2013;7(1):7-27, DOI: 10.1007/s12181-012-0478-8.

118. Gohlke H, Albus C, Bönner G, et al. CME Zertifizierte Fortbildung. Empfehlungen der Projektgruppe Prävention der DGK zur risikoadjustierten Prävention von Herz- und Kreislauferkrankungen. Teil 4: Thrombozytenfunktionshemmer, Hormonersatztherapie, Verhaltensänderung und psychosoziale Risikofaktoren. Kardiologe 2013;7(4):297-306, DOI: 10.1007/s12181-012-0469-9.

119. Albus C, Ladwig KH, Herrmann-Lingen C. Psychokardiologie: praxisrelevante Erkenntnisse und Handlungsempfehlungen. Dtsch Med Wochenschr 2014;139(12):596-601 http://www.ncbi.nlm.nih.gov/pubmed/24619718, DOI: 10.1055/s-0033-1360102.

120. Hachamovitch R, Hayes SW, Friedman JD, et al. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 2003;107(23):2900-7 http://www.ncbi.nlm.nih.gov/pubmed/12771008.

121. New York University School of Medicine (NYU). International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA). 2015 [cited: 2015 Juli 06]. Available from: http://clinicaltrials.gov/ct2/show/record/NCT01471522?term=
International+Study+of+Comparative+Health+Effectiveness+
With+Medical+and+Invasive+Approaches+%28ISCHEMIA%29&rank=1

122. Carson P, Wertheimer J, Miller A, et al. The STICH trial (Surgical Treatment for Ischemic Heart Failure): mode-of-death results. JACC Heart Fail 2013;1(5):400-8 http://www.ncbi.nlm.nih.gov/pubmed/24621972, DOI: 10.1016/j.jchf.2013.04.012.

123. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14(8):803-69 http://www.ncbi.nlm.nih.gov/pubmed/22828712, DOI: 10.1093/eurjhf/hfs105.

124. Bax JJ, Delgado V. Myocardial viability as integral part of the diagnostic and therapeutic approach to ischemic heart failure. J Nucl Cardiol 2015;22(2):229-45 http://www.ncbi.nlm.nih.gov/pubmed/25733105, DOI: 10.1007/s12350-015-0096-5.

125. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30(6):473-83 http://www.ncbi.nlm.nih.gov/pubmed/1593914.

126. Morfeld M, Kirchberger I, Bullinger M. SF-36. Fragebogen zum Gesundheitszustand. 2nd ed. Göttingen: Hogrefe; 2011.

127. Spertus JA, Winder JA, Dewhurst TA, et al. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. Journal of the American College of Cardiology 1995;25(2):333-41 http://www.ncbi.nlm.nih.gov/pubmed/7829785.

128. Höfer S, Benzer W, Schüssler G, et al. Health-related quality of life in patients with coronary artery disease treated for angina: validity and reliability of German translations of two specific questionnaires. Qual Life Res 2003;12(2):199-212 http://www.ncbi.nlm.nih.gov/pubmed/12639066.

129. Ware J, Jr., Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34(3):220-33 http://www.ncbi.nlm.nih.gov/pubmed/8628042.

130. Oldridge N, Guyatt G, Jones N, et al. Effects on quality of life with comprehensive rehabilitation after acute myocardial infarction. Am J Cardiol 1991;67(13):1084-9 http://www.ncbi.nlm.nih.gov/pubmed/2024598.

131. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy 1990;16(3):199-208 http://www.ncbi.nlm.nih.gov/pubmed/10109801.

132. Siegrist J, Broer M, Junge A. PLC. Profil der Lebensqualität chronisch Kranker. Göttingen: Hogrefe; 1995.

133. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009;119(23):3028-35 http://www.ncbi.nlm.nih.gov/pubmed/19528344, DOI: 10.1161/CIRCULATIONAHA.108.768986.

134. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353(5):487-97 http://www.ncbi.nlm.nih.gov/pubmed/16079372, DOI: 10.1056/NEJMra050100.

135. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 2007;167(6):540-50 http://www.ncbi.nlm.nih.gov/pubmed/17389285.

136. Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J 2013;34(38):2940-8 http://www.ncbi.nlm.nih.gov/pubmed/23907142, DOI: 10.1093/eurheartj/eht295.

137. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med 2012;125(9):882-7 http://www.ncbi.nlm.nih.gov/pubmed/22748400, DOI: 10.1016/j.amjmed.2011.12.013.

138. Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013;31(4):766-74 http://www.ncbi.nlm.nih.gov/pubmed/23337469, DOI: 10.1097/HJH.0b013e32835e2286.

139. Dietz R, Rauch B. Leitlinie zur Diagnose und Behandlung der chronischen koronaren Herzerkrankung der Deutschen Gesellschaft für Kardiologie- Herz- und Kreislaufforschung (DGK). In Kooperation mit der Deutschen Gesellschaft fur Prävention und Rehabilitation von Herz-Kreislauferkrankungen (DGPR) und der Deutschen Gesellschaft fur Thorax-, Herz- und Gefässchirurgie (DGTHG). Z Kardiol 2003;92(6):501-21 http://www.ncbi.nlm.nih.gov/pubmed/12905980.

140. Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ). Empfehlungen zur Prophylaxe und Therapie der stabilen koronaren Herzkrankheit. Köln: AkdÄ; 2004 (Arzneiverordnung in der Praxis; 31). Available from: http://www.akdae.de/Arzneimitteltherapie/TE/A-Z/PDF/KHK.pdf#page=1&view=fitB.

141. de Lorgeril M, Salen P, Defaye P, et al. Dietary prevention of sudden cardiac death. Eur Heart J 2002;23(4):277-85 http://www.ncbi.nlm.nih.gov/pubmed/11812063.

142. Haskell WL, Alderman EL, Fair JM, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994;89(3):975-90 http://www.ncbi.nlm.nih.gov/pubmed/8124838.

143. Niebauer J, Hambrecht R, Velich T, et al. Attenuated progression of coronary artery disease after 6 years of multifactorial risk intervention: role of physical exercise. Circulation 1997;96(8):2534-41 http://www.ncbi.nlm.nih.gov/pubmed/9355890.

144. Sdringola S, Nakagawa K, Nakagawa Y, et al. Combined intense lifestyle and pharmacologic lipid treatment further reduce coronary events and myocardial perfusion abnormalities compared with usual-care cholesterol-lowering drugs in coronary artery disease. Journal of the American College of Cardiology 2003;41(2):263-72 http://www.ncbi.nlm.nih.gov/pubmed/12535820.

145. Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999;341(6):427-34 http://www.ncbi.nlm.nih.gov/pubmed/10432328.

146. Smith SC, Jr., Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113(19):2363-72 http://www.ncbi.nlm.nih.gov/pubmed/16702489.

147. Deutsche Gesellschaft für Kardiologie (DGK). Primärprävention kardiovaskulärer Erkrankungen. Z Kardiol 2005;94(III1):114.

148. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7-22 http://www.ncbi.nlm.nih.gov/pubmed/12114036.

149. National Cholesterol Education Program (NCEP), National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106(25):3143-421 http://www.ncbi.nlm.nih.gov/pubmed/12485966.

150. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323(19):1289-98 http://www.ncbi.nlm.nih.gov/pubmed/2215615.

151. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999;282(24):2340-6 http://www.ncbi.nlm.nih.gov/pubmed/10612322.

152. Cheung BM, Lauder IJ, Lau CP, et al. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 2004;57(5):640-51 http://www.ncbi.nlm.nih.gov/pubmed/15089818.

153. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366(9493):1267-78 http://www.ncbi.nlm.nih.gov/pubmed/16214597.

154. Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ). Empfehlungen zur Therapie von Fettstoffwechselstörungen. 2nd ed. Köln: AkdÄ; 1999 (Arzneiverordnung in der Praxis; 1999).

155. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344(8934):1383-9 http://www.ncbi.nlm.nih.gov/pubmed/7968073.

156. Byington RP, Davis BR, Plehn JF, et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation 2001;103(3):387-92 http://www.ncbi.nlm.nih.gov/pubmed/11157690.

157. Endres M, Laufs U. HMG-CoA-Reduktasehemmer und Schlaganfallrisiko. Nervenarzt 1998;69(8):717-21 http://www.ncbi.nlm.nih.gov/pubmed/9757426.

158. Fihn SD, Williams SV, Daley J, et al. Guidelines for the management of patients with chronic stable angina: treatment. Ann Intern Med 2001;135(8 Pt 1):616-32 http://www.ncbi.nlm.nih.gov/pubmed/11601935.

159. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). Journal of the American College of Cardiology 2003;41(1):159-68 http://www.ncbi.nlm.nih.gov/pubmed/12570960.

160. Hebert PR, Gaziano JM, Chan KS, et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997;278(4):313-21 http://www.ncbi.nlm.nih.gov/pubmed/9228438.

161. Mosca L, Grundy SM, Judelson D, et al. AHA/ACC scientific statement: consensus panel statement. Guide to preventive cardiology for women. American Heart Association/American College of Cardiology. Journal of the American College of Cardiology 1999;33(6):1751-5 http://www.ncbi.nlm.nih.gov/pubmed/10334455.

162. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335(14):1001-9 http://www.ncbi.nlm.nih.gov/pubmed/8801446.

163. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361(9364):1149-58 http://www.ncbi.nlm.nih.gov/pubmed/12686036.

164. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333(20):1301-7 http://www.ncbi.nlm.nih.gov/pubmed/7566020.

165. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). Journal of the American College of Cardiology 1999;33(7):2092-197 http://www.ncbi.nlm.nih.gov/pubmed/10362225.

166. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ 2000;321(7267):983-6 http://www.ncbi.nlm.nih.gov/pubmed/11039962.

167. Laufs U, Donner-Banzhoff N, Popert U. Lipidsenkung mit Statinen: Titration oder feste Dosis. Dtsch Arztebl 2004;101(23):A-1649-51.

168. Deutsche Diabetes Gesellschaft (DDG), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Leitlinien der Deutschen Diabetes-Gesellschaft: Diabetes mellitus Typ 2. 2002 [cited: 2005 Oct 21].

169. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359(9311):995-1003 http://www.ncbi.nlm.nih.gov/pubmed/11937178.

170. Moser M. Current recommendations for the treatment of hypertension: are they still valid? J Hypertens 2002;20 Suppl 1:S3-10 http://www.ncbi.nlm.nih.gov/pubmed/11996197.

171. van den Hoogen PC, Feskens EJ, Nagelkerke NJ, et al. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med 2000;342(1):1-8 http://www.ncbi.nlm.nih.gov/pubmed/10620642.

172. Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ). Empfehlungen zur Therapie der arteriellen Hypertonie. 2nd ed. Köln: AkdÄ; 2004 (Arzneiverordnung in der Praxis; 31). Available from: http://www.akdae.de/Arzneimitteltherapie/TE/A-Z/PDF/Hypertonie.pdf.

173. Deutsche Liga zur Bekämpfung des hohen Blutdruckes, Deutsche Hypertonie Gesellschaft. Hypertonie. Empfehlungen zur Hochdruckbehandlung. Heidelberg: 2001.

174. European Society of Hypertension, European Society of Cardiology. 2003 Guidelines for the management of arterial hypertension. J Hypertens 2003;21(6):1011-53 http://www.ncbi.nlm.nih.gov/pubmed/12777938.

175. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289(19):2560-72 http://www.ncbi.nlm.nih.gov/pubmed/12748199.

176. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288(23):2981-97 http://www.ncbi.nlm.nih.gov/pubmed/12479763.

177. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348(7):583-92 http://www.ncbi.nlm.nih.gov/pubmed/12584366.

178. Deutsche Hochdruckliga (DHL), Deutsche Hypertonie Gesellschaft. Leitlinien für die Prävention, Erkennung, Diagnostik und Therapie der arteriellen Hypertonie. Dtsch Med Wochenschr 2001;126(Suppl. 4):S201-S238.

179. National Institutes of Health (NIH), National Heart, Lung and Blood Institute (NHLBI), Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157(21):2413-46 http://www.ncbi.nlm.nih.gov/pubmed/9385294.

180. World Health Organisation, International Society of Hypertension. 1999 Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999;17(2):151-83 http://www.ncbi.nlm.nih.gov/pubmed/10067786.

181. Beilin LJ, Puddey IB. Alcohol, hypertension and cardiovascular disease--implications for management. Clin Exp Hypertens 1993;15(6):1157-70 http://www.ncbi.nlm.nih.gov/pubmed/8268882.

182. de Wardener HE, MacGregor GA. Sodium and blood pressure. Curr Opin Cardiol 2002;17(4):360-7 http://www.ncbi.nlm.nih.gov/pubmed/12151870.

183. Whelton SP, Chin A, Xin X, et al. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med 2002;136(7):493-503 http://www.ncbi.nlm.nih.gov/pubmed/11926784.

184. American Diabetes Association (ADA). Clinical practice recommendations 2002. Diabetes Care 2002;25 Suppl 1:S1-147 http://www.ncbi.nlm.nih.gov/pubmed/11788484.

185. Erhardt L, Herlitz J, Bossaert L, et al. Task force on the management of chest pain. Eur Heart J 2002;23(15):1153-76 http://www.ncbi.nlm.nih.gov/pubmed/12206127.

186. UK Prospective Diabetes Study (UKPDS) Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317(7160):713-20 http://www.ncbi.nlm.nih.gov/pubmed/9732338.

187. Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med 2004;140(8):650-8 http://www.ncbi.nlm.nih.gov/pubmed/15096337.

188. Koller M, Lorenz W. Quality of life: a deconstruction for clinicians. J R Soc Med 2002;95(10):481-8 http://www.ncbi.nlm.nih.gov/pubmed/12356967.

189. Juniper EF, Guyatt GH, Ferrie PJ, et al. Measuring quality of life in asthma. Am Rev Respir Dis 1993;147(4):832-8 http://www.ncbi.nlm.nih.gov/pubmed/8466117.

190. McColl E, Steen IN, Meadows KA, et al. Developing outcome measures for ambulatory care--an application to asthma and diabetes. Soc Sci Med 1995;41(10):1339-48 http://www.ncbi.nlm.nih.gov/pubmed/8560301.

191. Bunker SJ, Colquhoun DM, Esler MD, et al. "Stress" and coronary heart disease: psychosocial risk factors. Med J Aust 2003;178(6):272-6 http://www.ncbi.nlm.nih.gov/pubmed/12633484.

192. Hemingway H, Malik M, Marmot M. Social and psychosocial influences on sudden cardiac death, ventricular arrhythmia and cardiac autonomic function. Eur Heart J 2001;22(13):1082-101 http://www.ncbi.nlm.nih.gov/pubmed/11428849.

193. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 1999;99(16):2192-217 http://www.ncbi.nlm.nih.gov/pubmed/10217662.

194. Bucher HC, Hengstler P, Schindler C, et al. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2002;112(4):298-304 http://www.ncbi.nlm.nih.gov/pubmed/11893369.

195. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989;2(8666):757-61 http://www.ncbi.nlm.nih.gov/pubmed/2571009.

196. de Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999;99(6):779-85 http://www.ncbi.nlm.nih.gov/pubmed/9989963.

197. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):23-33 http://www.ncbi.nlm.nih.gov/pubmed/12114037.

198. Ajani UA, Gaziano JM, Lotufo PA, et al. Alcohol consumption and risk of coronary heart disease by diabetes status. Circulation 2000;102(5):500-5 http://www.ncbi.nlm.nih.gov/pubmed/10920060.

199. Stampfer MJ, Hu FB, Manson JE, et al. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000;343(1):16-22 http://www.ncbi.nlm.nih.gov/pubmed/10882764.

200. Jacques PF, Selhub J, Bostom AG, et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999;340(19):1449-54 http://www.ncbi.nlm.nih.gov/pubmed/10320382.

201. Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001;345(22):1593-600 http://www.ncbi.nlm.nih.gov/pubmed/11757505.

202. Lange H, Suryapranata H, de Luca G, et al. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 2004;350(26):2673-81 http://www.ncbi.nlm.nih.gov/pubmed/15215483.

203. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354(15):1578-88 http://www.ncbi.nlm.nih.gov/pubmed/16531614.

204. Deutsche Adipositas-Gesellschaft (DAG). Leitlinien der Deutschen Adipositas-Gesellschaft zur Therapie der Adipositas. Adipositas 1998;8(16):6-28.

205. Yusuf S, Dagenais G, Pogue J, et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342(3):154-60 http://www.ncbi.nlm.nih.gov/pubmed/10639540.

206. Goldberg IJ, Mosca L, Piano MR, et al. AHA Science Advisory: Wine and your heart: a science advisory for healthcare professionals from the Nutrition Committee, Council on Epidemiology and Prevention, and Council on Cardiovascular Nursing of the American Heart Association. Circulation 2001;103(3):472-5 http://www.ncbi.nlm.nih.gov/pubmed/11157703.

207. Gronbaek M, Becker U, Johansen D, et al. Type of alcohol consumed and mortality from all causes, coronary heart disease, and cancer. Ann Intern Med 2000;133(6):411-9 http://www.ncbi.nlm.nih.gov/pubmed/10975958.

208. Keil U, Chambless LE, Doring A, et al. The relation of alcohol intake to coronary heart disease and all-cause mortality in a beer-drinking population. Epidemiology 1997;8(2):150-6 http://www.ncbi.nlm.nih.gov/pubmed/9229206.

209. Laufs U, Böhm M. Einfluss von Alkohol auf das kardiovaskuläre Risiko. Dtsch Z Sportmed 2001;52:227-30.

210. Renaud SC, Gueguen R, Schenker J, et al. Alcohol and mortality in middle-aged men from eastern France. Epidemiology 1998;9(2):184-8 http://www.ncbi.nlm.nih.gov/pubmed/9504288.

211. Rimm EB, Giovannucci EL, Willett WC, et al. Prospective study of alcohol consumption and risk of coronary disease in men. Lancet 1991;338(8765):464-8 http://www.ncbi.nlm.nih.gov/pubmed/1678444.

212. Sacco RL, Elkind M, Boden-Albala B, et al. The protective effect of moderate alcohol consumption on ischemic stroke. JAMA 1999;281(1):53-60 http://www.ncbi.nlm.nih.gov/pubmed/9892451.

213. Thun MJ, Peto R, Lopez AD, et al. Alcohol consumption and mortality among middle-aged and elderly U.S. adults. N Engl J Med 1997;337(24):1705-14 http://www.ncbi.nlm.nih.gov/pubmed/9392695.

214. Truelsen T, Gronbaek M, Schnohr P, et al. Intake of beer, wine, and spirits and risk of stroke : the copenhagen city heart study. Stroke 1998;29(12):2467-72 http://www.ncbi.nlm.nih.gov/pubmed/9836752.

215. Willett WC, Green A, Stampfer MJ, et al. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med 1987;317(21):1303-9 http://www.ncbi.nlm.nih.gov/pubmed/3683458.

216. Hjermann I, Velve BK, Holme I, et al. Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men. Lancet 1981;2(8259):1303-10 http://www.ncbi.nlm.nih.gov/pubmed/6118715.

217. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev 2004;(1):CD003041 http://www.ncbi.nlm.nih.gov/pubmed/14974003, DOI: 10.1002/14651858.CD003041.pub2.

218. Hermanson B, Omenn GS, Kronmal RA, et al. Beneficial six-year outcome of smoking cessation in older men and women with coronary artery disease. Results from the CASS registry. N Engl J Med 1988;319(21):1365-9 http://www.ncbi.nlm.nih.gov/pubmed/3185646.

219. Doll R, Peto R, Boreham J, et al. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004;328(7455):1519 http://www.ncbi.nlm.nih.gov/pubmed/15213107.

220. Lancaster T, Stead L. Physician advice for smoking cessation. Cochrane Database Syst Rev 2004;(4):CD000165 http://www.ncbi.nlm.nih.gov/pubmed/15494989.

221. Fichtenberg CM, Glantz SA. Effect of smoke-free workplaces on smoking behaviour: systematic review. BMJ 2002;325(7357):188 http://www.ncbi.nlm.nih.gov/pubmed/12142305.

222. Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ). Empfehlungen zur Therapie von Tabakabhängigkeit. Köln: AkdÄ; 2001 (Arzneiverordnung in der Praxis; 2001).

223. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. JAMA 1982;248(12):1465-77 http://www.ncbi.nlm.nih.gov/pubmed/7050440.

224. Peto R, Darby S, Deo H, et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000;321(7257):323-9 http://www.ncbi.nlm.nih.gov/pubmed/10926586.

225. Fletcher GF, Balady GJ, Amsterdam EA, et al. Exercise standards for testing and training: a statement for healthcare professionals from the American Heart Association. Circulation 2001;104(14):1694-740 http://www.ncbi.nlm.nih.gov/pubmed/11581152.

226. Gielen S, Schuler G, Hambrecht R. Exercise training in coronary artery disease and coronary vasomotion. Circulation 2001;103(1):E1-E6 http://www.ncbi.nlm.nih.gov/pubmed/11136704.

227. Hambrecht R, Wolf A, Gielen S, et al. Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med 2000;342(7):454-60 http://www.ncbi.nlm.nih.gov/pubmed/10675425.

228. Hambrecht R, Walther C, Mobius-Winkler S, et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. Circulation 2004;109(11):1371-8 http://www.ncbi.nlm.nih.gov/pubmed/15007010.

229. Joliffe JA, Rees K, Taylor RS, et al. Exercise-based rehabilitation for coronary heart disease (Cochrane Review). Cochrane Lib 2003;(1).

230. Miller TD, Balady GJ, Fletcher GF. Exercise and its role in the prevention and rehabilitation of cardiovascular disease. Ann Behav Med 1997;19(3):220-9 http://www.ncbi.nlm.nih.gov/pubmed/9603697.

231. Stewart KJ. Exercise training and the cardiovascular consequences of type 2 diabetes and hypertension: plausible mechanisms for improving cardiovascular health. JAMA 2002;288(13):1622-31 http://www.ncbi.nlm.nih.gov/pubmed/12350193.

232. Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 2004;116(10):682-92 http://www.ncbi.nlm.nih.gov/pubmed/15121495.

233. Agency for Health Care Policy and Research (AHCPR), U.S. Department of Health and Human Services. Cardiac rehabilitation. Rockville: AHCPR; 1995 (Clinical Practice Guideline; 17). Available from: http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat2.chapter.6677.

234. Heart Research Centre, Department of Human Services Victoria, Goble AJ, et al. Best Practice Guidelines for Cardiac Rehabilitation and Secondary Prevention. Melbourne: 1999 [cited: 2012 Mrz 13]. Available from: http://www.health.vic.gov.au/nhpa/card-resc.htm

235. New Zealand Guidelines Group (NZGG), New Zealand Heart Foundation. Cardiac Rehabilitation. Best Practice Evidence-Based Guideline. 2002 [cited: 2012 Mrz 13]. Available from: http://www.nzgg.org.nz/library_resources/30_cardiac_rehabilitation_guideline

236. Scottish Intercollegiate Guidelines Network (SIGN). Cardiac rehabilitation. Edinburgh: SIGN; 2002 (SIGN Publications; 57). Available from: http://www.sign.ac.uk/guidelines/published/numlist.html.

237. Gohlke H, Kübler W, Mathes P, et al. Empfehlungen zur umfassenden Risikoverringerung für Patienten mit koronarer Herzerkrankung, Gefässerkrankungen und Diabetes. Herausgegeben vom Vorstand der Deutschen Gesellschaft für Kardiologie-Herz- und Kreislaufforschung Bearbeitet im Auftrag der Kommission Klinische Kardiologie durch die Projektgruppe Prävention. Z Kardiol 2002;91 Suppl 2:61-2 http://www.ncbi.nlm.nih.gov/pubmed/12436766.

238. Thefeld W. Verbreitung der Herz-Kreislauf-Risikofaktoren Hypercholesterinämie, Übergewicht, Hypertonie und Rauchen in der Bevölkerung. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2000;43:415-23 http://www.springerlink.com/content/tf81r2e5f8dey570/.

239. Manson JE, Hu FB, Rich-Edwards JW, et al. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med 1999;341(9):650-8 http://www.ncbi.nlm.nih.gov/pubmed/10460816.

240. Manson JE, Greenland P, LaCroix AZ, et al. Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med 2002;347(10):716-25 http://www.ncbi.nlm.nih.gov/pubmed/12213942.

241. Schuler G, Hambrecht R, Schlierf G, et al. Myocardial perfusion and regression of coronary artery disease in patients on a regimen of intensive physical exercise and low fat diet. Journal of the American College of Cardiology 1992;19(1):34-42 http://www.ncbi.nlm.nih.gov/pubmed/1729343.

242. Jolliffe JA, Rees K, Taylor RS, et al. Exercise-based rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2001;(1):CD001800 http://www.ncbi.nlm.nih.gov/pubmed/11279730.

243. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308(6921):81-106 http://www.ncbi.nlm.nih.gov/pubmed/8298418.

244. Gum PA, Thamilarasan M, Watanabe J, et al. Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: A propensity analysis. JAMA 2001;286(10):1187-94 http://www.ncbi.nlm.nih.gov/pubmed/11559263.

245. Lauer MS. Clinical practice. Aspirin for primary prevention of coronary events. N Engl J Med 2002;346(19):1468-74 http://www.ncbi.nlm.nih.gov/pubmed/12000818.

246. Juul-Moller S, Edvardsson N, Jahnmatz B, et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992;340(8833):1421-5 http://www.ncbi.nlm.nih.gov/pubmed/1360557.

247. Manson JE, Grobbee DE, Stampfer MJ, et al. Aspirin in the primary prevention of angina pectoris in a randomized trial of United States physicians. Am J Med 1990;89(6):772-6 http://www.ncbi.nlm.nih.gov/pubmed/2252045.

248. Manson JE, Tosteson H, Ridker PM, et al. The primary prevention of myocardial infarction. N Engl J Med 1992;326(21):1406-16 http://www.ncbi.nlm.nih.gov/pubmed/1533273.

249. Ridker PM, Manson JE, Gaziano JM, et al. Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. Ann Intern Med 1991;114(10):835-9 http://www.ncbi.nlm.nih.gov/pubmed/2014943.

250. Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 2002;162(19):2197-202 http://www.ncbi.nlm.nih.gov/pubmed/12390062.

251. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373(9678):1849-60 http://www.ncbi.nlm.nih.gov/pubmed/19482214.

252. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352(13):1293-304 http://www.ncbi.nlm.nih.gov/pubmed/15753114.

253. Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295(3):306-13 http://www.ncbi.nlm.nih.gov/pubmed/16418466.

254. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329):71-86 http://www.ncbi.nlm.nih.gov/pubmed/11786451.

255. Campbell CL, Smyth S, Montalescot G, et al. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 2007;297(18):2018-24 http://www.ncbi.nlm.nih.gov/pubmed/17488967.

256. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Clopidogrel versus Acetylsalicylsäure in der Sekundärprophylaxe vaskulärer Erkrankungen. Abschlussbericht. Auftrag A04-01A. Version 1.0. 2006 [cited: 2011 Okt 17]. Available from: http://www.iqwig.de/download/A04-01A_Abschlussbericht_Clopidogrel_versus_ASS_in_der_Sekundaerprophylaxe.pdf

257. Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. Journal of the American College of Cardiology 2005;45(2):246-51 http://www.ncbi.nlm.nih.gov/pubmed/15653023.

258. Creager MA. Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events. Vasc Med 1998;3(3):257-60 http://www.ncbi.nlm.nih.gov/pubmed/9892520.

259. Harker LA, Boissel JP, Pilgrim AJ, et al. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Drug Saf 1999;21(4):325-35 http://www.ncbi.nlm.nih.gov/pubmed/10514023.

260. Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102(6):624-9 http://www.ncbi.nlm.nih.gov/pubmed/10931801.

261. Neubauer H, Krüger JC, Lask S, et al. Comparing the antiplatelet effect of clopidogrel hydrogensulfate and clopidogrel besylate: a crossover study. Clin Res Cardiol 2009;98(9):533-40 http://www.ncbi.nlm.nih.gov/pubmed/19504141.

262. Berger J, Bugnon O. Herrscht ein weiterer «Salzkrieg»? Clopidogrelgenerika. Ars Medici 2010;14:570-2 http://www.rosenfluh.ch/rosenfluh/articles/download/1571/Herrscht_ein_weiterer_Salzkrieg.pdf.

263. Darius H, Münzel T, Huber K, et al. Clopidogrel Salts - Pharmacokinetic, Pharmakodynamic and Clinical Aspects. J Kardiol 2009;16(11-12):412-6 http://www.kup.at/kup/pdf/8410.pdf.

264. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357(20):2001-15 http://www.ncbi.nlm.nih.gov/pubmed/17982182.

265. Gemeinsamer Bundesausschuss (G-BA). Beschluss des Gemeinsamen Bundesausschusses über die Einleitung eines Stellungnahmeverfahrens zur Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage IV – Therapiehinweis zu Prasugrel. 2009 [cited: 2011 Okt 17]. Available from: http://www.g-ba.de/downloads/39-261-868/2009-08-20-AMR4-SN-Prasugrel.pdf

266. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361(11):1045-57 http://www.ncbi.nlm.nih.gov/pubmed/19717846.

267. Europäische Kommission. Beschluss der Kommission vom 3.12.2010 über die Erteilung einer Zulassung für das Humanarzneimittel "Brilique - Ticagrelor" gemäß der Verordnung (EG) Nr. 726/2004 des Europäischen Parlaments und des Rates. 2010 [cited: 2011 Okt 17]. Available from: http://ec.europa.eu/health/documents/community-register/2010/2010120390969/dec_90969_de.pdf

268. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Ticagrelor – Nutzenbewertung gemäß § 35a SGB V. Dossierbewertung. Auftrag A11-02. Version 1.0. 2011 [cited: 2014 Sep 09]. Available from: http://www.iqwig.de/download/A11-02_Ticagrelor_Nutzenbewertung_35a_SGB_V_.pdf

269. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1(8649):1215-20 http://www.ncbi.nlm.nih.gov/pubmed/2566778.

270. Hass WK, Easton JD, Adams HP, Jr., et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989;321(8):501-7 http://www.ncbi.nlm.nih.gov/pubmed/2761587.

271. Gemeinsamer Bundesausschuss (G-BA). Therapiehinweis nach Ziffer 14 Arzneimittel-Richtlinien Clopidogrel (z.B. Plavix, Iscover). 2000 [cited: 2011 Okt 17]. Available from: http://www.g-ba.de/downloads/39-261-401/2000_02_16_AMR_4-Clopidogrel.pdf

272. Bhatt DL, Bertrand ME, Berger PB, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. Journal of the American College of Cardiology 2002;39(1):9-14 http://www.ncbi.nlm.nih.gov/pubmed/11755280.

273. National Institute for Clinical Excellence (NICE). Drug-eluting stents for the treatment of coronary artery disease. Part review of NICE technology technology appraisal guidance 71. London: NICE; 2008 (Technology Appraisal Guidance; 152).

274. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010;31(20):2501-55 http://www.ncbi.nlm.nih.gov/pubmed/20802248.

275. Becker RC, Meade TW, Berger PB, et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):776S-814S http://www.ncbi.nlm.nih.gov/pubmed/18574278.

276. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008;118(18):1894-909 http://www.ncbi.nlm.nih.gov/pubmed/18836135.

277. Trenk D. Proton pump inhibitors for prevention of bleeding episodes in cardiac patients with dual antiplatelet therapy - between Scylla and Charybdis? Int J Clin Pharmacol Ther 2009;47(1):1-10 http://www.ncbi.nlm.nih.gov/pubmed/19203527.

278. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Circulation 2010; http://www.ncbi.nlm.nih.gov/pubmed/21060077.

279. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180(7):713-8 http://www.ncbi.nlm.nih.gov/pubmed/19176635.

280. European Medicines Agency (EMA). Clopidogrel HEXAL 75 mg film-coated tablets - Summary of product characteristics. 2007 [cited: 2011 Okt 17]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001139/WC500028929.pdf

281. Food and Drug Administration (FDA). Information on Clopidogrel Bisulfate (marketed as Plavix). 2010 [cited: 2011 Okt 17]. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm190836.htm

282. Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am J Gastroenterol 2010;105(1):34-41 http://www.ncbi.nlm.nih.gov/pubmed/19904241.

283. Lin SL, Chang HM, Liu CP, et al. Clinical evidence of interaction between clopidogrel and proton pump inhibitors. World J Cardiol 2011;3(5):153-64 http://www.ncbi.nlm.nih.gov/pubmed/21666816.

284. Taha AS, McCloskey C, Prasad R, et al. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 2009;374(9684):119-25 http://www.ncbi.nlm.nih.gov/pubmed/19577798.

285. Charlot M, Grove EL, Hansen PR, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ 2011;342:d2690 http://www.ncbi.nlm.nih.gov/pubmed/21562004.

286. Hermosillo AJ, Spinler SA. Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous? Ann Pharmacother 2008;42(6):790-805 http://www.ncbi.nlm.nih.gov/pubmed/18477734.

287. Dentali F, Douketis JD, Lim W, et al. Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med 2007;167(2):117-24 http://www.ncbi.nlm.nih.gov/pubmed/17242311.

288. Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002;347(13):969-74 http://www.ncbi.nlm.nih.gov/pubmed/12324552.

289. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA 1999;282(21):2058-67 http://www.ncbi.nlm.nih.gov/pubmed/10591389.

290. Lip GY, Huber K, Andreotti F, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 2010;103(1):13-28 http://www.ncbi.nlm.nih.gov/pubmed/20062939.

291. Rubboli A, Halperin JL, Airaksinen KE, et al. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Ann Med 2008;40(6):428-36 http://www.ncbi.nlm.nih.gov/pubmed/18608125.

292. Rubboli A, Colletta M, Valencia J, et al. Periprocedural management and in-hospital outcome of patients with indication for oral anticoagulation undergoing coronary artery stenting. J Interv Cardiol 2009;22(4):390-7 http://www.ncbi.nlm.nih.gov/pubmed/19453820.

293. Gilard M, Blanchard D, Helft G, et al. Antiplatelet therapy in patients with anticoagulants undergoing percutaneous coronary stenting (from STENTIng and oral antiCOagulants [STENTICO]). Am J Cardiol 2009;104(3):338-42 http://www.ncbi.nlm.nih.gov/pubmed/19616664.

294. Baran KW, Lasala JM, Cox DA, et al. A clinical risk score for prediction of stent thrombosis. Am J Cardiol 2008;102(5):541-5 http://www.ncbi.nlm.nih.gov/pubmed/18721509.

295. Lip GY, Huber K, Andreotti F, et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2010;31(11):1311-8 http://www.ncbi.nlm.nih.gov/pubmed/20447945.

296. Testa L, Zoccai GB, Porto I, et al. Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes. Am J Cardiol 2007;99(12):1637-42 http://www.ncbi.nlm.nih.gov/pubmed/17560866.

297. Sörensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009;374(9706):1967-74 http://www.ncbi.nlm.nih.gov/pubmed/20006130.

298. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002;105(3):310-5 http://www.ncbi.nlm.nih.gov/pubmed/11804985.

299. Martin MJ, Hulley SB, Browner WS, et al. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet 1986;2(8513):933-6 http://www.ncbi.nlm.nih.gov/pubmed/2877128.

300. Briel M, Ferreira-Gonzalez I, You JJ, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009;338:b92 http://www.ncbi.nlm.nih.gov/pubmed/19221140.

301. Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ). Arzneiverordnungen. Empfehlungen zur rationalen Pharmakotherapie. 22nd ed. Neu-Isenburg: MMI; 2009.

302. Delahoy PJ, Magliano DJ, Webb K, et al. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. Clin Ther 2009;31(2):236-44 http://www.ncbi.nlm.nih.gov/pubmed/19302897.

303. Cholesterol Treatment Trialists' Ctt Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010;376(9753):1670-81 http://www.ncbi.nlm.nih.gov/pubmed/21067804.

304. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45:89-118 http://www.ncbi.nlm.nih.gov/pubmed/15822172.

305. Wilt TJ, Bloomfield HE, MacDonald R, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 2004;164:1427-36 http://www.ncbi.nlm.nih.gov/pubmed/15249352.

306. Aung PP, Maxwell HG, Jepson RG, et al. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev 2007;(4):CD000123 http://www.ncbi.nlm.nih.gov/pubmed/17943736.

307. Coppola G, Novo S. Statins and peripheral arterial disease: effects on claudication, disease progression, and prevention of cardiovascular events. Arch Med Res 2007;38(5):479-88 http://www.ncbi.nlm.nih.gov/pubmed/17560452.

308. Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol 1998;81(3):333-5 http://www.ncbi.nlm.nih.gov/pubmed/9468077.

309. Weng TC, Yang YH, Lin SJ, et al. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 2010;35(2):139-51 http://www.ncbi.nlm.nih.gov/pubmed/20456733.

310. Afilalo J, Duque G, Steele R, et al. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. Journal of the American College of Cardiology 2008;51(1):37-45 http://www.ncbi.nlm.nih.gov/pubmed/18174034.

311. Roberts CG, Guallar E, Rodriguez A. Efficacy and safety of statin monotherapy in older adults: a meta-analysis. J Gerontol A Biol Sci Med Sci 2007;62(8):879-87 http://www.ncbi.nlm.nih.gov/pubmed/17702880.

312. Ridker PM, MacFadyen JG, Fonseca FA, et al. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circ Cardiovasc Qual Outcomes 2009;2(6):616-23 http://www.ncbi.nlm.nih.gov/pubmed/20031900.

313. Mora S, Glynn RJ, Hsia J, et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 2010;121(9):1069-77 http://www.ncbi.nlm.nih.gov/pubmed/20176986.

314. Shalev V, Chodick G, Silber H, et al. Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med 2009;169(3):260-8 http://www.ncbi.nlm.nih.gov/pubmed/19204217.

315. Penning-van Beest FJ, Termorshuizen F, Goettsch WG, et al. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 2007;28(2):154-9 http://www.ncbi.nlm.nih.gov/pubmed/17158123.

316. Spencer FA, Allegrone J, Goldberg RJ, et al. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med 2004;140(11):857-66 http://www.ncbi.nlm.nih.gov/pubmed/15172899.

317. Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002;105(12):1446-52 http://www.ncbi.nlm.nih.gov/pubmed/11914253.

318. Wu JY, Leung WY, Chang S, et al. Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomised controlled trial. BMJ 2006;333(7567):522 http://www.ncbi.nlm.nih.gov/pubmed/16916809.

319. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 2006;296(21):2563-71 http://www.ncbi.nlm.nih.gov/pubmed/17101639.

320. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357(22):2248-61 http://www.ncbi.nlm.nih.gov/pubmed/17984166.

321. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360(14):1395-407 http://www.ncbi.nlm.nih.gov/pubmed/19332456.

322. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353(3):238-48 http://www.ncbi.nlm.nih.gov/pubmed/16034009.

323. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372(9645):1231-9 http://www.ncbi.nlm.nih.gov/pubmed/18757089.

324. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97(8A):52C-60C http://www.ncbi.nlm.nih.gov/pubmed/16581329.

325. National Institute for Health and Clinical Excellence (NICE), Nherera L, Calvert N, et al. Clinical Guidelines and Evidence Review for Lipid Modification: cardiovascular risk assessment and the primary and secondary prevention of cardiovascular disease. London: NICE; 2008 (NICE Clinical Guideline; 67). Available from: http://www.nice.org.uk/guidance/cg67/resources/guidance-lipid-modification-cardiovascular-risk-assessment-and-the-modification-of-blood-lipids-for-the-primary-and-secondary-prevention-of-cardiovascular-disease-pdf.

326. Armitage J. The safety of statins in clinical practice. Lancet 2007;370(9601):1781-90 http://www.ncbi.nlm.nih.gov/pubmed/17559928.

327. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. Journal of the American College of Cardiology 2006;48(3):438-45 http://www.ncbi.nlm.nih.gov/pubmed/16875966.

328. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther 2005;19(6):403-14 http://www.ncbi.nlm.nih.gov/pubmed/16453090.

329. U.S. Food and Drug Administration (FDA). FDA Drug Safety Communication: Ongoing safety review of high-dose Zocor (simvastatin) and increased risk of muscle injury. 2010 [cited: 2011 Sep 16]. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm204882.htm

330. Armitage J, Bowman L, Wallendszus K, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010;376(9753):1658-69 http://www.ncbi.nlm.nih.gov/pubmed/21067805.

331. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292(11):1307-16 http://www.ncbi.nlm.nih.gov/pubmed/15337732.

332. U.S. Food and Drug Administration (FDA). FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. 2011 [cited: 2011 Sep 16]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm

333. Trommsdorff GmbH & Co. KG. Fachinformation "Zodin® 1000 mg Weichkapseln". 2005 [cited: 2011 Sep 16]. Available from: http://www.trommsdorff.de/fileadmin/trommsdorff/redaktion/Fachbereich/Zodin_1000_mg_Weichkapseln.pdf

334. Solvay Arzneimittel GmbH. Fachinformation "Lipidil® 200 mg". 2008.

335. Pfizer Pharma GmbH. Fachinformation "Sortis®". 2008.

336. Parke-Davis GmbH, Pfizer Pharma GmbH. Fachinformation "Gevilon®". 2008.

337. Novartis Pharma GmbH. Fachinformation "Locol® 20 mg Hartkapseln, Locol® 40 mg Hartkapseln". 2007.

338. Gohlke H, Albus C, Bönner G, et al. Leitlinie Risikoadjustierte Prävention von Herz- und Kreislauferkrankungen. 2007 [cited: 2011 Okt 17]. Available from: http://leitlinien.dgk.org/images/pdf/leitlinien_volltext/2007-10_Risikoadjustierte.pdf

339. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007;28(19):2375-414 http://www.ncbi.nlm.nih.gov/pubmed/17726041.

340. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110(2):227-39 http://www.ncbi.nlm.nih.gov/pubmed/15249516.

341. Rahilly-Tierney CR, Lawler EV, Scranton RE, et al. Cardiovascular benefit of magnitude of low-density lipoprotein cholesterol reduction: a comparison of subgroups by age. Circulation 2009;120(15):1491-7 http://www.ncbi.nlm.nih.gov/pubmed/19786636.

342. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350(15):1495-504 http://www.ncbi.nlm.nih.gov/pubmed/15007110.

343. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352(14):1425-35 http://www.ncbi.nlm.nih.gov/pubmed/15755765.

344. Koren MJ, Hunninghake DB. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. Journal of the American College of Cardiology 2004;44(9):1772-9 http://www.ncbi.nlm.nih.gov/pubmed/15519006.

345. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291(9):1071-80 http://www.ncbi.nlm.nih.gov/pubmed/14996776.

346. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction: The IDEAL Study: A Randomized Controlled Trial. JAMA 2005;294(19):2437-45 http://www.ncbi.nlm.nih.gov/pubmed/16287954.

347. Wei L, MacDonald TM, Watson AD, et al. Effectiveness of two statin prescribing strategies with respect to adherence and cardiovascular outcomes: observational study. Pharmacoepidemiol Drug Saf 2007;16(4):385-92 http://www.ncbi.nlm.nih.gov/pubmed/16998946.

348. The Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995;345(8960):1274-5 http://www.ncbi.nlm.nih.gov/pubmed/7746058.

349. Laufs U, Rettig-Ewen V, Bohm M. Strategies to improve drug adherence. Eur Heart J 2010;in press http://www.ncbi.nlm.nih.gov/pubmed/20729544.

350. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371(9607):117-25 http://www.ncbi.nlm.nih.gov/pubmed/18191683.

351. Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160(4):459-67 http://www.ncbi.nlm.nih.gov/pubmed/10695686.

352. McBride P, Schrott HG, Plane MB, et al. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med 1998;158(11):1238-44 http://www.ncbi.nlm.nih.gov/pubmed/9625403.

353. Jackevicius CA, Tu JV, Ross JS, et al. Use of ezetimibe in the United States and Canada. N Engl J Med 2008;358(17):1819-28 http://www.ncbi.nlm.nih.gov/pubmed/18375999.

354. Donner-Banzhoff N, Sönnichsen A. Strategies for prescribing statins. BMJ 2008;336(7639):288-9 http://www.ncbi.nlm.nih.gov/pubmed/18258935.

355. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis 1967;20(8):637-48 http://www.ncbi.nlm.nih.gov/pubmed/4860352.

356. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010;375(9729):1875-84 http://www.ncbi.nlm.nih.gov/pubmed/20462635.

357. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366(9500):1849-61 http://www.ncbi.nlm.nih.gov/pubmed/16310551.

358. ACCORD Study Group. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus (ACCORD). N Engl J Med 2010; http://www.ncbi.nlm.nih.gov/pubmed/20228404.

359. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257(23):3233-40 http://www.ncbi.nlm.nih.gov/pubmed/3295315.

360. Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation 1984;69(2):313-24 http://www.ncbi.nlm.nih.gov/pubmed/6360414.

361. Ruoff G. Colestipol hydrochloride for treatment of hypercholesterolemia in a family practice: five-year study. J Am Geriatr Soc 1978;26(3):121-6 http://www.ncbi.nlm.nih.gov/pubmed/624819.

362. Watts GF, Lewis B, Brunt JN, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992;339(8793):563-9 http://www.ncbi.nlm.nih.gov/pubmed/1347091.

363. Dorr AE, Gundersen K, Schneider JC, Jr., et al. Colestipol hydrochloride in hypercholesterolemic patients--effect on serum cholesterol and mortality. J Chronic Dis 1978;31(1):5-14 http://www.ncbi.nlm.nih.gov/pubmed/346598.

364. Bays HE, Davidson M, Jones MR, et al. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol 2006;97(8):1198-205 http://www.ncbi.nlm.nih.gov/pubmed/16616026.

365. European Medical Agency (EMA). Cholestagel. European Public Assessment Report. 2009 [cited: 2011 Okt 17]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/
human/medicines/000512/human_med_000697.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125

366. Insull W, Jr., Toth P, Mullican W, et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc 2001;76(10):971-82 http://www.ncbi.nlm.nih.gov/pubmed/11605698.

367. Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001;110(5):352-60 http://www.ncbi.nlm.nih.gov/pubmed/11286949.

368. Bays HE, Moore PB, Drehobl MA, et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 2001;23(8):1209-30 http://www.ncbi.nlm.nih.gov/pubmed/11558859.

369. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. Journal of the American College of Cardiology 2002;40(12):2125-34 http://www.ncbi.nlm.nih.gov/pubmed/12505224.

370. Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90(10):1092-7 http://www.ncbi.nlm.nih.gov/pubmed/12423709.

371. Ezzet F, Wexler D, Statkevich P, et al. The plasma concentration and LDL-C relationship in patients receiving ezetimibe. J Clin Pharmacol 2001;41(9):943-9 http://www.ncbi.nlm.nih.gov/pubmed/11549098.

372. Goldberg AC, Sapre A, Liu J, et al. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004;79(5):620-9 http://www.ncbi.nlm.nih.gov/pubmed/15132403.

373. Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003;24(8):729-41 http://www.ncbi.nlm.nih.gov/pubmed/12713767.

374. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358(14):1431-43 http://www.ncbi.nlm.nih.gov/pubmed/18376000.

375. Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359(13):1343-56 http://www.ncbi.nlm.nih.gov/pubmed/18765433.

376. Farnier M, Averna M, Missault L, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. Int J Clin Pract 2009;63(4):547-59 http://www.ncbi.nlm.nih.gov/pubmed/19222610.

377. Fichtlscherer S, Schmidt-Lucke C, Bojunga S, et al. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy. Eur Heart J 2006;27(10):1182-90 http://www.ncbi.nlm.nih.gov/pubmed/16621868.

378. Pearson TA, Denke MA, McBride PE, et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005;80(5):587-95 http://www.ncbi.nlm.nih.gov/pubmed/15887425.

379. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003;107(19):2409-15 http://www.ncbi.nlm.nih.gov/pubmed/12719279.

380. Kerzner B, Corbelli J, Sharp S, et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003;91(4):418-24 http://www.ncbi.nlm.nih.gov/pubmed/12586255.

381. Melani L, Mills R, Hassman D, et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 2003;24(8):717-28 http://www.ncbi.nlm.nih.gov/pubmed/12713766.

382. Gagne C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90(10):1084-91 http://www.ncbi.nlm.nih.gov/pubmed/12423708.

383. Hartweg J, Farmer AJ, Perera R, et al. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes. Diabetologia 2007;50(8):1593-602 http://www.ncbi.nlm.nih.gov/pubmed/17541540.

384. Leon H, Shibata MC, Sivakumaran S, et al. Effect of fish oil on arrhythmias and mortality: systematic review. BMJ 2008;337:a2931 http://www.ncbi.nlm.nih.gov/pubmed/19106137.

385. Studer M, Briel M, Leimenstoll B, et al. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med 2005;165(7):725-30 http://www.ncbi.nlm.nih.gov/pubmed/15824290.

386. Hooper L, Thompson RL, Harrison RA, et al. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ 2006;332(7544):752-60 http://www.ncbi.nlm.nih.gov/pubmed/16565093.

387. Hooper L, Thompson RL, Harrison RA, et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev 2004;(4):CD003177 http://www.ncbi.nlm.nih.gov/pubmed/15495044.

388. DeMott K, Nherera L, Shaw EJ, et al. Clinical Guidelines and Evidence Review for Familial hypercholesterolaemia: the identification and management of adults and children with familial hypercholesterolaemia. London: NCCPC;RCGP; 2008 Available from: http://www.nice.org.uk/guidance/cg71/resources/cg71-familial-hypercholesterolaemia-full-guideline3.

389. Management Committee. The Australian therapeutic trial in mild hypertension. Report. Lancet 1980;1(8181):1261-7 http://www.ncbi.nlm.nih.gov/pubmed/6104081.

390. MRC working party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992;304(6824):405-12 http://www.ncbi.nlm.nih.gov/pubmed/1445513.

391. Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991;338(8778):1281-5 http://www.ncbi.nlm.nih.gov/pubmed/1682683.

392. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998;279(23):1903-7 http://www.ncbi.nlm.nih.gov/pubmed/9634263.

393. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997;277(9):739-45 http://www.ncbi.nlm.nih.gov/pubmed/9042847.

394. Tuomilehto J, Wikstrand J, Warnold I, et al. Coronary artery disease can be prevented by antihypertensive therapy: experiences from the MAPHY Study. J Cardiovasc Pharmacol 1990;16 Suppl 7:S75-S76 http://www.ncbi.nlm.nih.gov/pubmed/1708032.

395. Wikstrand J, Warnold I, Olsson G, et al. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 1988;259(13):1976-82 http://www.ncbi.nlm.nih.gov/pubmed/3346979.

396. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665 http://www.ncbi.nlm.nih.gov/pubmed/19454737.

397. Miller DB. Secondary prevention for ischemic heart disease. Relative numbers needed to treat with different therapies. Arch Intern Med 1997;157(18):2045-52 http://www.ncbi.nlm.nih.gov/pubmed/9382659.

398. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27(5):335-71 http://www.ncbi.nlm.nih.gov/pubmed/2858114.

399. Freemantle N, Cleland J, Young P, et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318(7200):1730-7 http://www.ncbi.nlm.nih.gov/pubmed/10381708.

400. Olsson G, Wikstrand J, Warnold I, et al. Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J 1992;13(1):28-32 http://www.ncbi.nlm.nih.gov/pubmed/1533587.

401. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339(8):489-97 http://www.ncbi.nlm.nih.gov/pubmed/9709041.

402. Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. Eur Heart J 2007;28(24):3012-9 http://www.ncbi.nlm.nih.gov/pubmed/17981830.

403. Klapholz M. Beta-blocker use for the stages of heart failure. Mayo Clin Proc 2009;84(8):718-29 http://www.ncbi.nlm.nih.gov/pubmed/19648389.

404. Shibata MC, Flather MD, Wang D. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail 2001;3(3):351-7 http://www.ncbi.nlm.nih.gov/pubmed/11378007.

405. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation 2001;104(24):2996-3007 http://www.ncbi.nlm.nih.gov/pubmed/11739319.

406. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz. 2009 [cited: 2011 Okt 17]. Available from: http://www.versorgungsleitlinien.de/themen/herzinsuffizienz

407. Hackam DG, Khan NA, Hemmelgarn BR, et al. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol 2010;26(5):249-58 http://www.ncbi.nlm.nih.gov/pubmed/20485689.

408. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004;364(9446):1684-9 http://www.ncbi.nlm.nih.gov/pubmed/15530629.

409. Bradford WD, Chen J, Krumholz HM. Under-utilisation of beta-blockers after acute myocardial infarction. Pharmacoeconomic implications. Pharmacoeconomics 1999;15(3):257-68 http://www.ncbi.nlm.nih.gov/pubmed/10537433.

410. Dahlof C, Dimenas E, Kendall M, et al. Quality of life in cardiovascular diseases. Emphasis on beta-blocker treatment. Circulation 1991;84(6 Suppl):VI108-VI118 http://www.ncbi.nlm.nih.gov/pubmed/1683605.

411. Herlitz J, Malmberg K. How to improve the cardiac prognosis for diabetes. Diabetes Care 1999;22 Suppl 2:B89-B96 http://www.ncbi.nlm.nih.gov/pubmed/10097907.

412. Labbe L, Sirois C, Pilote S, et al. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 2000;10(5):425-38 http://www.ncbi.nlm.nih.gov/pubmed/10898112.

413. Luzier AB, Killian A, Wilton JH, et al. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 1999;66(6):594-601 http://www.ncbi.nlm.nih.gov/pubmed/10613615.

414. Walle T, Byington RP, Furberg CD, et al. Biologic determinants of propranolol disposition: results from 1308 patients in the Beta-Blocker Heart Attack Trial. Clin Pharmacol Ther 1985;38(5):509-18 http://www.ncbi.nlm.nih.gov/pubmed/4053488.

415. Thürmann PA, Haack S, Werner U, et al. Tolerability of beta-blockers metabolized via cytochrome P450 2D6 is sex-dependent. Clin Pharmacol Ther 2006;80(5):551-3 http://www.ncbi.nlm.nih.gov/pubmed/17112812.

416. Jochmann N, Stangl K, Garbe E, et al. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J 2005;26(16):1585-95 http://www.ncbi.nlm.nih.gov/pubmed/15996977.

417. Ghali JK, Pina IL, Gottlieb SS, et al. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation 2002;105(13):1585-91 http://www.ncbi.nlm.nih.gov/pubmed/11927527.

418. Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372(9641):807-16 http://www.ncbi.nlm.nih.gov/pubmed/18757088, DOI: 10.1016/S0140-6736(08)61170-8.

419. Fox K, Ford I, Steg PG, et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 2009;30(19):2337-45 http://www.ncbi.nlm.nih.gov/pubmed/19720635, DOI: 10.1093/eurheartj/ehp358.

420. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376(9744):875-85 http://www.ncbi.nlm.nih.gov/pubmed/20801500, DOI: 10.1016/S0140-6736(10)61198-1.

421. Böhm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010; http://www.ncbi.nlm.nih.gov/pubmed/20801495.

422. Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2002;89(2A):18A-25A http://www.ncbi.nlm.nih.gov/pubmed/11835907.

423. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327(10):669-77 http://www.ncbi.nlm.nih.gov/pubmed/1386652.

424. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316(23):1429-35 http://www.ncbi.nlm.nih.gov/pubmed/2883575.

425. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325(5):293-302 http://www.ncbi.nlm.nih.gov/pubmed/2057034.

426. Shekelle P, Rich M, Morton S, et al. Pharmacologic Management of Heart Failure and Left Ventricular Systolic Dysfunction: Effect in Female, Black, and Diabetic Patients, and Cost-Effectiveness. Evidence Report/Technology Assessment No. 82 (Prepared by the Southern California Evidence-based Practice Center, under Contract No. 290-97-0001). AHRQ Publication Number 03-E045. 2003 [cited: 2011 Okt 17]. Available from: http://www.ahrq.gov/downloads/pub/evidence/pdf/heartfailure/heartfail.pdf

427. Saha SA, Molnar J, Arora RR. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials. J Cardiovasc Pharmacol Ther 2007;12(3):192-204 http://www.ncbi.nlm.nih.gov/pubmed/17875946.

428. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342(3):145-53 http://www.ncbi.nlm.nih.gov/pubmed/10639539.

429. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362(9386):782-8 http://www.ncbi.nlm.nih.gov/pubmed/13678872.

430. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351(20):2058-68 http://www.ncbi.nlm.nih.gov/pubmed/15531767.

431. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004;292(18):2217-25 http://www.ncbi.nlm.nih.gov/pubmed/15536108.

432. Pitt B, O'Neill B, Feldman R, et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001;87(9):1058-63 http://www.ncbi.nlm.nih.gov/pubmed/11348602.

433. Fischer M, Baessler A, Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res 2002;53(3):672-7 http://www.ncbi.nlm.nih.gov/pubmed/11861038.

434. Harrison-Bernard LM, Schulman IH, Raij L. Postovariectomy hypertension is linked to increased renal AT1 receptor and salt sensitivity. Hypertension 2003;42(6):1157-63 http://www.ncbi.nlm.nih.gov/pubmed/14610098.

435. Harvey PJ, Morris BL, Miller JA, et al. Estradiol induces discordant angiotensin and blood pressure responses to orthostasis in healthy postmenopausal women. Hypertension 2005;45(3):399-405 http://www.ncbi.nlm.nih.gov/pubmed/15699442.

436. Schunkert H, Danser AH, Hense HW, et al. Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation 1997;95(1):39-45 http://www.ncbi.nlm.nih.gov/pubmed/8994414.

437. Regitz-Zagrosek V, Schubert C, Kruger S. Geschlechterunterschiede in der kardiovaskulären Pharmakotherapie. Internist (Berl) 2008;49(11):1383-90 http://www.ncbi.nlm.nih.gov/pubmed/18839124.

438. Mackay FJ, Pearce GL, Mann RD. Cough and angiotensin II receptor antagonists: cause or confounding? Br J Clin Pharmacol 1999;47(1):111-4 http://www.ncbi.nlm.nih.gov/pubmed/10073748.

439. Kubota K, Kubota N, Pearce GL, et al. ACE-inhibitor-induced cough, an adverse drug reaction unrecognised for several years: studies in prescription-event monitoring. Eur J Clin Pharmacol 1996;49(6):431-7 http://www.ncbi.nlm.nih.gov/pubmed/8706766.

440. Strocchi E, Malini PL, Valtancoli G, et al. Cough during treatment with angiotensin-converting enzyme inhibitors. Analysis of predisposing factors. Drug Invest 1992;4:69-72.

441. Svensson P, de FU, Sleight P, et al. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 2001;38(6):E28-E32 http://www.ncbi.nlm.nih.gov/pubmed/11751742.

442. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358(15):1547-59 http://www.ncbi.nlm.nih.gov/pubmed/18378520.

443. Kasanuki H, Hagiwara N, Hosoda S, et al. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009;30(10):1203-12 http://www.ncbi.nlm.nih.gov/pubmed/19346521.

444. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349(20):1893-906 http://www.ncbi.nlm.nih.gov/pubmed/14610160.

445. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362(9386):772-6 http://www.ncbi.nlm.nih.gov/pubmed/13678870.

446. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360(9335):752-60 http://www.ncbi.nlm.nih.gov/pubmed/12241832.

447. Gradman AH, Schmieder RE, Lins RL, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005;111(8):1012-8 http://www.ncbi.nlm.nih.gov/pubmed/15723979.

448. Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007;8(4):190-8 http://www.ncbi.nlm.nih.gov/pubmed/18205098.

449. Verdecchia P, Calvo C, Mockel V, et al. Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Press 2007;16(6):381-91 http://www.ncbi.nlm.nih.gov/pubmed/18058456.

450. Dietz R, Dechend R, Yu CM, et al. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension. J Renin Angiotensin Aldosterone Syst 2008;9(3):163-75 http://www.ncbi.nlm.nih.gov/pubmed/18957387.

451. Schmieder RE, Philipp T, Guerediaga J, et al. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial. J Hypertens 2009;27(7):1493-501 http://www.ncbi.nlm.nih.gov/pubmed/19444142.

452. Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007;20(1):11-20 http://www.ncbi.nlm.nih.gov/pubmed/17198906.

453. Strasser RH, Puig JG, Farsang C, et al. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. J Hum Hypertens 2007;21(10):780-7 http://www.ncbi.nlm.nih.gov/pubmed/17541390.

454. Jordan J, Engeli S, Boye SW, et al. Direct Renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007;49(5):1047-55 http://www.ncbi.nlm.nih.gov/pubmed/17353513.

455. Andersen K, Weinberger MH, Egan B, et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008;26(3):589-99 http://www.ncbi.nlm.nih.gov/pubmed/18300872.

456. Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007;370(9583):221-9 http://www.ncbi.nlm.nih.gov/pubmed/17658393.

457. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358(23):2433-46 http://www.ncbi.nlm.nih.gov/pubmed/18525041.

458. Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009;119(4):530-7 http://www.ncbi.nlm.nih.gov/pubmed/19153265.

459. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274(8):620-5 http://www.ncbi.nlm.nih.gov/pubmed/7637142.

460. Teerlink JR, Massie BM. Beta-adrenergic blocker mortality trials in congestive heart failure. Am J Cardiol 1999;84(9A):94R-102R http://www.ncbi.nlm.nih.gov/pubmed/10568667.

461. Laufs U, Erdmann E. Therapie der Herzinsuffizienz mit Beta-Rezeptoren-Blockern. Herz Kreisl 1999;31:363-6.

462. MRC working party. Mild hypertension. Report. BMJ 1988;297(6650):739 http://www.ncbi.nlm.nih.gov/pubmed/3147750.

463. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353(9153):611-6 http://www.ncbi.nlm.nih.gov/pubmed/10030325.

464. Costanzo P, Perrone-Filardi P, Petretta M, et al. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients. J Hypertens 2009;27(6):1136-51 http://www.ncbi.nlm.nih.gov/pubmed/19451836.

465. Bangalore S, Parkar S, Messerli FH. Long-acting calcium antagonists in patients with coronary artery disease: a meta-analysis. Am J Med 2009;122(4):356-65 http://www.ncbi.nlm.nih.gov/pubmed/19332231.

466. Krecic-Shepard ME, Barnas CR, Slimko J, et al. Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. J Clin Pharmacol 2000;40(3):219-30 http://www.ncbi.nlm.nih.gov/pubmed/10709150.

467. Krecic-Shepard ME, Park K, Barnas C, et al. Race and sex influence clearance of nifedipine: results of a population study. Clin Pharmacol Ther 2000;68(2):130-42 http://www.ncbi.nlm.nih.gov/pubmed/10976544.

468. Kloner RA, Sowers JR, DiBona GF, et al. Sex- and age-related antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group. Am J Cardiol 1996;77(9):713-22 http://www.ncbi.nlm.nih.gov/pubmed/8651122.

469. Kjeldsen SE, Kolloch RE, Leonetti G, et al. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. J Hypertens 2000;18(5):629-42 http://www.ncbi.nlm.nih.gov/pubmed/10826567.

470. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356(9227):366-72 http://www.ncbi.nlm.nih.gov/pubmed/10972368.

471. Fagard RH, Staessen JA, Thijs L, et al. Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Circulation 2000;102(10):1139-44 http://www.ncbi.nlm.nih.gov/pubmed/10973843.

472. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354(9192):1751-6 http://www.ncbi.nlm.nih.gov/pubmed/10577635.

473. Kjeldsen SE, Hedner T, Syvertsen JO, et al. Influence of age, sex and blood pressure on the principal endpoints of the Nordic Diltiazem (NORDIL) Study. J Hypertens 2002;20(6):1231-7 http://www.ncbi.nlm.nih.gov/pubmed/12023696.

474. Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 1997;96(3):856-63 http://www.ncbi.nlm.nih.gov/pubmed/9264493.

475. Elkayam U, Amin J, Mehra A, et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990;82(6):1954-61 http://www.ncbi.nlm.nih.gov/pubmed/2242521.

476. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112(12):e154-e235 http://www.ncbi.nlm.nih.gov/pubmed/16160202.

477. Levine TB, Bernink PJ, Caspi A, et al. Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH-1 study. Mortality Assessment in Congestive Heart Failure Trial. Circulation 2000;101(7):758-64 http://www.ncbi.nlm.nih.gov/pubmed/10683349.

478. Littler WA, Sheridan DJ. Placebo controlled trial of felodipine in patients with mild to moderate heart failure. UK Study Group. Br Heart J 1995;73(5):428-33 http://www.ncbi.nlm.nih.gov/pubmed/7786657.

479. Mullins ME, Horowitz BZ, Linden DH, et al. Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers. JAMA 1998;280(2):157-8 http://www.ncbi.nlm.nih.gov/pubmed/9669789.

480. Tan LB, Murray RG, Littler WA. Felodipine in patients with chronic heart failure: discrepant haemodynamic and clinical effects. Br Heart J 1987;58(2):122-8 http://www.ncbi.nlm.nih.gov/pubmed/3304372.

481. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996;335(15):1107-14 http://www.ncbi.nlm.nih.gov/pubmed/8813041.

482. Hillis LD, Braunwald E. Coronary-artery spasm. N Engl J Med 1978;299(13):695-702 http://www.ncbi.nlm.nih.gov/pubmed/210380.

483. Emanuelsson H, Ake H, Kristi M, et al. Effects of diltiazem and isosorbide-5-mononitrate, alone and in combination, on patients with stable angina pectoris. Eur J Clin Pharmacol 1989;36(6):561-6 http://www.ncbi.nlm.nih.gov/pubmed/2506059.

484. Ankier SI, Fay L, Warrington SJ, et al. A multicentre open comparison of isosorbide-5-mononitrate and nifedipine given prophylactically to general practice patients with chronic stable angina pectoris. J Int Med Res 1989;17(2):172-8 http://www.ncbi.nlm.nih.gov/pubmed/2656333.

485. Schneider W, Maul FD, Bussmann WD, et al. Comparison of the antianginal efficacy of isosorbide dinitrate (ISDN) 40 mg and verapamil 120 mg three times daily in the acute trial and following two-week treatment. Eur Heart J 1988;9(2):149-58 http://www.ncbi.nlm.nih.gov/pubmed/3280317.

486. Tirlapur VG, Mir MA. Cardiorespiratory effects of isosorbide dinitrate and nifedipine in combination with nadolol: a double-blind comparative study of beneficial and adverse antianginal drug interactions. Am J Cardiol 1984;53(4):487-92 http://www.ncbi.nlm.nih.gov/pubmed/6141727.

487. Bassan MM, Weiler-Ravell D. The additive antianginal action of oral isosorbide dinitrate in patients receiving propranolol. Magnitude and duration of effect. Chest 1983;83(2):233-40 http://www.ncbi.nlm.nih.gov/pubmed/6822108.

488. Bassan MM, Weiler-Ravell D, Shalev O. Comparison of the antianginal effectiveness of nifedipine, verapamil, and isosorbide dinitrate in patients receiving propranolol: a double-blind study. Circulation 1983;68(3):568-75 http://www.ncbi.nlm.nih.gov/pubmed/6872169.

489. Akhras F, Jackson G. Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina. Lancet 1991;338(8774):1036-9 http://www.ncbi.nlm.nih.gov/pubmed/1681355.

490. Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. N Engl J Med 1998;338(8):520-31 http://www.ncbi.nlm.nih.gov/pubmed/9468470.

491. Abrams J. A reappraisal of nitrate therapy. JAMA 1988;259(3):396-401 http://www.ncbi.nlm.nih.gov/pubmed/3275814.

492. Corwin S, Reiffel JA. Nitrate therapy for angina pectoris. Current concepts about mechanism of action and evaluation of currently available preparations. Arch Intern Med 1985;145(3):538-43 http://www.ncbi.nlm.nih.gov/pubmed/3919668.

493. Held P. Effects of nitrates on mortality in acute myocardial infarction and in heart failure. Br J Clin Pharmacol 1992;34 Suppl 1:25S-8S http://www.ncbi.nlm.nih.gov/pubmed/1633075.

494. Thadani U, Lipicky RJ. Short and long-acting oral nitrates for stable angina pectoris. Cardiovasc Drugs Ther 1994;8(4):611-23 http://www.ncbi.nlm.nih.gov/pubmed/7848896.

495. Chrysant SG, Glasser SP, Bittar N, et al. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris. Am J Cardiol 1993;72(17):1249-56 http://www.ncbi.nlm.nih.gov/pubmed/8256699.

496. Akhras F, Hellestrand K, Whalley D, et al. Efficacy of intermittent (eight hours off) transdermal nitrate therapy in stable angina. Int J Cardiol 1994;43(3):251-6 http://www.ncbi.nlm.nih.gov/pubmed/8181883.

497. Akhras F, Chambers J, Jefferies S, et al. A randomised double-blind crossover study of isosorbide mononitrate and nifedipine retard in chronic stable angina. Int J Cardiol 1989;24(2):191-6 http://www.ncbi.nlm.nih.gov/pubmed/2504673.

498. Feelisch M. The use of nitric oxide donors in pharmacological studies. Naunyn Schmiedebergs Arch Pharmacol 1998;358(1):113-22 http://www.ncbi.nlm.nih.gov/pubmed/9721012.

499. Parker JO, Amies MH, Hawkinson RW, et al. Intermittent transdermal nitroglycerin therapy in angina pectoris. Clinically effective without tolerance or rebound. Minitran Efficacy Study Group. Circulation 1995;91(5):1368-74 http://www.ncbi.nlm.nih.gov/pubmed/7867175.

500. Wainwright RJ, Foran JP, Padaria SF, et al. The long-term safety and tolerability of transdermal glyceryl trinitrate, when used with a patch-free interval in patients with stable angina. Br J Clin Pract 1993;47(4):178-82 http://www.ncbi.nlm.nih.gov/pubmed/8260332.

501. Gori T, Parker JD. Nitrate tolerance: a unifying hypothesis. Circulation 2002;106(19):2510-3 http://www.ncbi.nlm.nih.gov/pubmed/12417551.

502. DeBusk R, Drory Y, Goldstein I, et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of The Princeton Consensus Panel. Am J Cardiol 2000;86(2):175-81 http://www.ncbi.nlm.nih.gov/pubmed/10913479.

503. DiFrancesco D, Camm JA. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs 2004;64(16):1757-65 http://www.ncbi.nlm.nih.gov/pubmed/15301560.

504. Er F, Hoppe UC. Ivabradin - Ein neues Prinzip zur Herzfrequenzsenkung. Dtsch Med Wochenschr 2005;130(24):1501-2 http://www.ncbi.nlm.nih.gov/pubmed/15942839.

505. DiFrancesco D. Cardiac pacemaker I(f) current and its inhibition by heart rate-reducing agents. Curr Med Res Opin 2005;21(7):1115-22 http://www.ncbi.nlm.nih.gov/pubmed/16004681.

506. European Medical Agency (EMA). Procoralan. European Public Assesment Report. 2010 [cited: 2011 Okt 17]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000597/human_med_000995.jsp&mid=WC0b01ac058001d124

507. Borer JS, Fox K, Jaillon P, et al. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 2003;107(6):817-23 http://www.ncbi.nlm.nih.gov/pubmed/12591750.

508. Tardif JC, Ford I, Tendera M, et al. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005;26(23):2529-36 http://www.ncbi.nlm.nih.gov/pubmed/16214830.

509. Tardif JC, Ponikowski P, Kahan T. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009;30(5):540-8 http://www.ncbi.nlm.nih.gov/pubmed/19136486.

510. Michels G, Kochanek M, Hoppe UC. Ranolazin - ein ergänzendes Antianginosum. Dtsch Med Wochenschr 2010;135(41):2037-40 http://www.ncbi.nlm.nih.gov/pubmed/20925013.

511. European Medical Agency (EMEA). CHMP Asessment Report For Latixa. Nonproprietary Name: ranolazine. Procedure No. EMEA/H/C/805. EMEA/CHMP/30876/2008. London: EMA; 2008.

512. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004;43(8):1375-82 http://www.ncbi.nlm.nih.gov/pubmed/15093870.

513. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004;291(3):309-16 http://www.ncbi.nlm.nih.gov/pubmed/14734593.

514. Stone PH, Gratsiansky NA, Blokhin A, et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006;48(3):566-75 http://www.ncbi.nlm.nih.gov/pubmed/16875985.

515. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 2007;297(16):1775-83 http://www.ncbi.nlm.nih.gov/pubmed/17456819.

516. Wenger NK, Chaitman B, Vetrovec GW. Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials. Am J Cardiol 2007;99(1):11-8 http://www.ncbi.nlm.nih.gov/pubmed/17196454.

517. Keller T, Weeda VB, van Dongen CJ, et al. Influenza vaccines for preventing coronary heart disease. Cochrane Database Syst Rev 2008;(3):CD005050 http://www.ncbi.nlm.nih.gov/pubmed/18646119.

518. Robert Koch Institut (RKI). Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2010. Epidemiol Bull RKI 2010;(30):279-98.

519. Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG). Hormontherapie in der Peri- und Postmenopause (HT). 2009 [cited: 2011 Okt 17]. Available from: http://www.uni-duesseldorf.de/awmf/ll/015-062.htm

520. Seely DM, Wu P, Mills EJ. EDTA chelation therapy for cardiovascular disease: a systematic review. BMC Cardiovasc Disord 2005;5:32 http://www.ncbi.nlm.nih.gov/pubmed/16262904.

521. Zhuo Q, Yuan Z, Chen H, et al. Traditional Chinese herbal products for stable angina. Cochrane Database Syst Rev 2010;5:CD004468 http://www.ncbi.nlm.nih.gov/pubmed/20464731.

522. Asplund K. Antioxidant vitamins in the prevention of cardiovascular disease: a systematic review. J Int Med 2002;251(5):372-92 http://www.ncbi.nlm.nih.gov/pubmed/11982737.

523. Sesso HD, Buring JE, Christen WG, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA 2008;300(18):2123-33 http://www.ncbi.nlm.nih.gov/pubmed/18997197.

524. Sänger S, Lang B, Klemperer D, et al. Manual Patienteninformation. Empfehlungen zur Erstellung evidenzbasierter Patienteninformationen. Berlin: ÄZQ; 2006 (äzq Schriftenreihe; 25). Available from: http://www.aezq.de/mdb/edocs/pdf/schriftenreihe/schriftenreihe25.pdf.

525. Deutsches Netzwerk Evidenzbasierte Medizin (DNEbM). Gute Praxis Gesundheitsinformation. Ein Positionspapier des Deutschen Netzwerks Evidenzbasierte Medizin. Version 2.0. Berlin: 2015 [cited: 2016 Jan 04]. Available from: http://www.ebm-netzwerk.de/pdf/publikationen/gpgi2.pdf

526. Elwyn G, O'Connor AM, Bennett C, et al. Assessing the Quality of Decision Support Technologies Using the International Patient Decision Aid Standards instrument (IPDASi). PLoS One 2009;4(3):e4705, DOI: 10.1371/journal.pone.0004705.

527. Sipahi I, Akay MH, Dagdelen S, et al. Coronary artery bypass grafting vs percutaneous coronary intervention and long-term mortality and morbidity in multivessel disease: meta-analysis of randomized clinical trials of the arterial grafting and stenting era. JAMA Intern Med 2014;174(2):223-30 http://www.ncbi.nlm.nih.gov/pubmed/24296767, DOI: 10.1001/jamainternmed.2013.12844.

528. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356(15):1503-16 http://www.ncbi.nlm.nih.gov/pubmed/17387127.

529. Thomas S, Gokhale R, Boden WE, et al. A meta-analysis of randomized controlled trials comparing percutaneous coronary intervention with medical therapy in stable angina pectoris. Can J Cardiol 2013;29(4):472-82 http://www.ncbi.nlm.nih.gov/pubmed/23010084, DOI: 10.1016/j.cjca.2012.07.010.

530. Stergiopoulos K, Boden WE, Hartigan P, et al. Percutaneous Coronary Intervention Outcomes in Patients With Stable Obstructive Coronary Artery Disease and Myocardial Ischemia: A Collaborative Meta-analysis of Contemporary Randomized Clinical Trials. JAMA Intern Med 2014;174(2):232-40 http://www.ncbi.nlm.nih.gov/pubmed/24296791, DOI: 10.1001/jamainternmed.2013.12855.

531. Pursnani S, Korley F, Gopaul R, et al. Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials. Circ Cardiovasc Interv 2012;5(4):476-90 http://www.ncbi.nlm.nih.gov/pubmed/22872053, DOI: 10.1161/CIRCINTERVENTIONS.112.970954.

532. Stergiopoulos K, Brown DL. Initial coronary stent implantation with medical therapy vs medical therapy alone for stable coronary artery disease: meta-analysis of randomized controlled trials. Arch Intern Med 2012;172(4):312-9 http://www.ncbi.nlm.nih.gov/pubmed/22371919, DOI: 10.1001/archinternmed.2011.1484.

533. Gorenoi V, Schonermark MP, Hagen A. Perkutane Koronarinterventionen zusätzlich zur optimalen medikamentösen Therapie bei stabiler Angina Pectoris. GMS Health Technol Assess 2011;7:Doc07 http://www.ncbi.nlm.nih.gov/pubmed/22205918.

534. Bangalore S, Pursnani S, Kumar S, et al. Percutaneous coronary intervention versus optimal medical therapy for prevention of spontaneous myocardial infarction in subjects with stable ischemic heart disease. Circulation 2013;127(7):769-81 http://www.ncbi.nlm.nih.gov/pubmed/23325526, DOI: 10.1161/CIRCULATIONAHA.112.131961.

535. Jeremias A, Kaul S, Rosengart TK, et al. The impact of revascularization on mortality in patients with nonacute coronary artery disease. Am J Med 2009;122(2):152-61 http://www.ncbi.nlm.nih.gov/pubmed/19185092.

536. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994;344(8922):563-70 http://www.ncbi.nlm.nih.gov/pubmed/7914958.

537. Hueb W, Lopes N, Gersh BJ, et al. Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2010;122(10):949-57 http://www.ncbi.nlm.nih.gov/pubmed/20733102.

538. Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011;364(17):1607-16 http://www.ncbi.nlm.nih.gov/pubmed/21463150.

539. Institut für angewandte Qualitätsförderung und Forschung im Gesundheitswesen (AQUA), Gemeinsamer Bundesausschuss (G-BA). Qualitätsreport 2012. Göttingen: AQUA; 2013 Available from: http://www.sqg.de/sqg/upload/CONTENT/Qualitaetsberichte/2012/AQUA-Qualitaetsreport-2012.pdf.

540. Wijeysundera HC, Nallamothu BK, Krumholz HM, et al. Meta-analysis: effects of percutaneous coronary intervention versus medical therapy on angina relief. Ann Intern Med 2010;152(6):370-9 http://www.ncbi.nlm.nih.gov/pubmed/20231568, DOI: 10.7326/0003-4819-152-6-201003160-00007.

541. Li Q, Zhang Z, Yin RX. Drug-eluting stents or coronary artery bypass grafting for unprotected left main coronary artery disease: a meta-analysis of four randomized trials and seventeen observational studies. Trials 2013;14:133 http://www.ncbi.nlm.nih.gov/pubmed/23782856, DOI: 10.1186/1745-6215-14-133.

542. Head SJ, Kaul S, Mack MJ, et al. The rationale for Heart Team decision-making for patients with stable, complex coronary artery disease. Eur Heart J 2013;34(32):2510-8 http://www.ncbi.nlm.nih.gov/pubmed/23425523, DOI: 10.1093/eurheartj/eht059.

543. Kapoor JR, Gienger AL, Ardehali R, et al. Isolated disease of the proximal left anterior descending artery comparing the effectiveness of percutaneous coronary interventions and coronary artery bypass surgery. JACC Cardiovasc Interv 2008;1(5):483-91 http://www.ncbi.nlm.nih.gov/pubmed/19463349.

544. Aziz O, Rao C, Panesar SS, et al. Meta-analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery. BMJ 2007;334(7594):617 http://www.ncbi.nlm.nih.gov/pubmed/17337458.

545. Blazek S, Holzhey D, Jungert C, et al. Comparison of bare-metal stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: 10-year follow-up of a randomized trial. JACC Cardiovasc Interv 2013;6(1):20-6 http://www.ncbi.nlm.nih.gov/pubmed/23347858, DOI: 10.1016/j.jcin.2012.09.008.

546. Thiele H, Neumann-Schniedewind P, Jacobs S, et al. Randomized comparison of minimally invasive direct coronary artery bypass surgery versus sirolimus-eluting stenting in isolated proximal left anterior descending coronary artery stenosis. J Am Coll Cardiol 2009;53(25):2324-31 http://www.ncbi.nlm.nih.gov/pubmed/19539141, DOI: 10.1016/j.jacc.2009.03.032.

547. Deb S, Wijeysundera HC, Ko DT, et al. Coronary artery bypass graft surgery vs percutaneous interventions in coronary revascularization: a systematic review. JAMA 2013;310(19):2086-95 http://www.ncbi.nlm.nih.gov/pubmed/24240936, DOI: 10.1001/jama.2013.281718.

548. Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013;381(9867):629-38 http://www.ncbi.nlm.nih.gov/pubmed/23439102, DOI: 10.1016/S0140-6736(13)60141-5.

549. Booth J, Clayton T, Pepper J, et al. Randomized, controlled trial of coronary artery bypass surgery versus percutaneous coronary intervention in patients with multivessel coronary artery disease: six-year follow-up from the Stent or Surgery Trial (SoS). Circulation 2008;118(4):381-8 http://www.ncbi.nlm.nih.gov/pubmed/18606919.

550. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009;360(10):961-72 http://www.ncbi.nlm.nih.gov/pubmed/19228612.

551. Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative effectiveness of revascularization strategies. N Engl J Med 2012;366(16):1467-76 http://www.ncbi.nlm.nih.gov/pubmed/22452338, DOI: 10.1056/NEJMoa1110717.

552. Fortuna D, Nicolini F, Guastaroba P, et al. Coronary artery bypass grafting vs percutaneous coronary intervention in a 'real-world' setting: a comparative effectiveness study based on propensity score-matched cohorts. Eur J Cardiothorac Surg 2013;44(1):e16-e24 http://www.ncbi.nlm.nih.gov/pubmed/23628951, DOI: 10.1093/ejcts/ezt197.

553. Takagi H, Yamamoto H, Iwata K, et al. Drug-eluting stents increase late mortality compared with coronary artery bypass grafting in triple-vessel disease: a meta-analysis of randomized controlled and risk-adjusted observational studies. Int J Cardiol 2012;159(3):230-3 http://www.ncbi.nlm.nih.gov/pubmed/22664367, DOI: 10.1016/j.ijcard.2012.05.046.

554. Kappetein AP, Head SJ, Morice MC, et al. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg 2013;43(5):1006-13 http://www.ncbi.nlm.nih.gov/pubmed/23413014, DOI: 10.1093/ejcts/ezt017.

555. Kapur A, Hall RJ, Malik IS, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. Journal of the American College of Cardiology 2010;55(5):432-40 http://www.ncbi.nlm.nih.gov/pubmed/20117456.

556. Li X, Kong M, Jiang D, et al. Comparing coronary artery bypass grafting with drug-eluting stenting in patients with diabetes mellitus and multivessel coronary artery disease: a meta-analysis. Interact Cardiovasc Thorac Surg 2014;18(3):347-54 http://www.ncbi.nlm.nih.gov/pubmed/24345688, DOI: 10.1093/icvts/ivt509.

557. Bundesärztekammer (BÄK), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Kassenärztliche Bundesvereinigung (KBV). Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes - Langfassung, 1. Auflage. Version 3. 2014 [cited: 2014 Jun 05]. Available from: http://doi.org/10.6101/AZQ/000203, DOI: 10.6101/AZQ/000203

558. Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009;360(24):2503-15 http://www.ncbi.nlm.nih.gov/pubmed/19502645.

559. Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for Multivessel Revascularization in Patients with Diabetes. N Engl J Med 2012; http://www.ncbi.nlm.nih.gov/pubmed/23121323, DOI: 10.1056/NEJMoa1211585.

560. Hakeem A, Garg N, Bhatti S, et al. Effectiveness of Percutaneous Coronary Intervention With Drug-Eluting Stents Compared With Bypass Surgery in Diabetics With Multivessel Coronary Disease: Comprehensive Systematic Review and Meta-analysis of Randomized Clinical Data. J Am Heart Assoc 2013;2(4):e000354 http://www.ncbi.nlm.nih.gov/pubmed/23926119, DOI: 10.1161/JAHA.113.000354.

561. Capodanno D, Stone GW, Morice MC, et al. Percutaneous coronary intervention versus coronary artery bypass graft surgery in left main coronary artery disease: a meta-analysis of randomized clinical data. J Am Coll Cardiol 2011;58(14):1426-32 http://www.ncbi.nlm.nih.gov/pubmed/21939824, DOI: 10.1016/j.jacc.2011.07.005.

562. Park SJ, Kim YH, Park DW, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease. N Engl J Med 2011;364(18):1718-27 http://www.ncbi.nlm.nih.gov/pubmed/21463149.

563. Morice MC, Serruys PW, Kappetein AP, et al. Five-Year Outcomes in Patients with Left Main Disease Treated with Either Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting in the SYNTAX Trial. Circulation 2014; www.ncbi.nlm.nih.gov/pubmed/24700706, DOI: 10.1161/CIRCULATIONAHA.113.006689.

564. Cao C, Manganas C, Bannon P, et al. Drug-eluting stents versus coronary artery bypass graft surgery in left main coronary artery disease: a meta-analysis of early outcomes from randomized and nonrandomized studies. J Thorac Cardiovasc Surg 2013;145(3):738-47 http://www.ncbi.nlm.nih.gov/pubmed/22405674, DOI: 10.1016/j.jtcvs.2012.02.004.

565. Sa MP, Soares AM, Lustosa PC, et al. Meta-analysis of 5674 patients treated with percutaneous coronary intervention and drug-eluting stents or coronary artery bypass graft surgery for unprotected left main coronary artery stenosis. Eur J Cardiothorac Surg 2013;43(1):73-80 http://www.ncbi.nlm.nih.gov/pubmed/22518037, DOI: 10.1093/ejcts/ezs204.

566. Taylor HA, Deumite NJ, Chaitman BR, et al. Asymptomatic left main coronary artery disease in the Coronary Artery Surgery Study (CASS) registry. Circulation 1989;79(6):1171-9 http://www.ncbi.nlm.nih.gov/pubmed/2785870.

567. Park DW, Kim YH, Yun SC, et al. Long-term outcomes after stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 10-year results of bare-metal stents and 5-year results of drug-eluting stents from the ASAN-MAIN (ASAN Medical Center-Left MAIN Revascularization) Registry. J Am Coll Cardiol 2010;56(17):1366-75 http://www.ncbi.nlm.nih.gov/pubmed/20946993.

568. Mehilli J, Kastrati A, Byrne RA, et al. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol 2009;53(19):1760-8 http://www.ncbi.nlm.nih.gov/pubmed/19422982, DOI: 10.1016/j.jacc.2009.01.035.

569. Taggart DP, Kaul S, Boden WE, et al. Revascularization for unprotected left main stem coronary artery stenosis stenting or surgery. J Am Coll Cardiol 2008;51(9):885-92 http://www.ncbi.nlm.nih.gov/pubmed/18308155, DOI: 10.1016/j.jacc.2007.09.067.

570. Boudriot E, Thiele H, Walther T, et al. Randomized comparison of percutaneous coronary intervention with sirolimus-eluting stents versus coronary artery bypass grafting in unprotected left main stem stenosis. J Am Coll Cardiol 2011;57(5):538-45 http://www.ncbi.nlm.nih.gov/pubmed/21272743.

571. Stone GW, Serruys PW, Sabik J, et al. Evaluation of XIENCE PRIME™ Everolimus Eluting Stent System (EECSS) or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization. 2013 [cited: 2014 Mar 18]. Available from: http://www.clinicaltrials.gov/ct2/show/study/NCT01205776

572. Buszman PE, Kiesz SR, Bochenek A, et al. Acute and late outcomes of unprotected left main stenting in comparison with surgical revascularization. J Am Coll Cardiol 2008;51(5):538-45 http://www.ncbi.nlm.nih.gov/pubmed/18237682.

573. Desch S, Boudriot E, Rastan A, et al. Bypass surgery versus percutaneous coronary intervention for the treatment of unprotected left main disease. A meta-analysis of randomized controlled trials. Herz 2013;38(1):48-56 http://www.ncbi.nlm.nih.gov/pubmed/22407425, DOI: 10.1007/s00059-012-3596-y.

574. Alam M, Huang HD, Shahzad SA, et al. Percutaneous coronary intervention vs. coronary artery bypass graft surgery for unprotected left main coronary artery disease in the drug-eluting stents era--an aggregate data meta-analysis of 11,148 patients. Circ J 2013;77(2):372-82 http://www.ncbi.nlm.nih.gov/pubmed/23123552.

575. Chieffo A, Meliga E, Latib A, et al. Drug-eluting stent for left main coronary artery disease. The DELTA registry: a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. JACC Cardiovasc Interv 2012;5(7):718-27 http://www.ncbi.nlm.nih.gov/pubmed/22814776, DOI: 10.1016/j.jcin.2012.03.022.

576. Farooq V, van KD, Steyerberg EW, et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet 2013;381(9867):639-50 http://www.ncbi.nlm.nih.gov/pubmed/23439103, DOI: 10.1016/S0140-6736(13)60108-7.

577. World Health Organization (WHO). Rehabilitation after cardiovascular diseases, with special emphasis on developing countries. Report of a WHO Expert Committee. WHO Tech Rep Ser 1993;831:1-122 http://www.ncbi.nlm.nih.gov/pubmed/8351937.

578. National Institute for Clinical Excellence (NICE), Centre for Health Services Research, University of Newcastle upon Tyne (CHSR), Medicines Evaluation Group, Centre for Health Econonmics, University of York. Prophylaxis for patients who have experienced a myocardial infarction: drug treatment, cardiac rehabilitation and dietary manipulation (Myocardial Infarction - Detailed Guideline). Newcastle upon Tyne: 2001 [cited: 2005 Jun 23]. Available from: http://www.nice.org.uk/page.aspx?o=20270

579. Dubach P, Myers J, Wagner D. Optimal timing of phase II rehabilitation after cardiac surgery. The cardiologist's view. Eur Heart J 1998;19 Suppl O:O35-O37 http://www.ncbi.nlm.nih.gov/pubmed/9857948.

580. Sachverständigenrat für die Konzertierte Aktion im Gesundheitswesen (SVR). Bedarfsgerechtigkeit und Wirtschaftlichkeit. Band II: Qualitätsentwicklung in Medizin und Pflege. Gutachten 2000/2001. Baden-Baden: Nomos; 2002 Available from: http://dip.bundestag.de/btd/14/056/1405661.pdf.

581. O'Connor GT, Buring JE, Yusuf S, et al. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation 1989;80(2):234-44 http://www.ncbi.nlm.nih.gov/pubmed/2665973.

582. Baessler A, Hengstenberg C, Holmer S, et al. Long-term effects of in-hospital cardiac rehabilitation on the cardiac risk profile. A case-control study in pairs of siblings with myocardial infarction. Eur Heart J 2001;22(13):1111-8 http://www.ncbi.nlm.nih.gov/pubmed/11428851.

583. Detry JR, Vierendeel IA, Vanbutsele RJ, et al. Early short-term intensive cardiac rehabilitation induces positive results as long as one year after the acute coronary event: a prospective one-year controlled study. J Cardiovasc Risk 2001;8(6):355-61 http://www.ncbi.nlm.nih.gov/pubmed/11873091.

584. Hamalainen H, Luurila OJ, Kallio V, et al. Reduction in sudden deaths and coronary mortality in myocardial infarction patients after rehabilitation. 15 year follow-up study. Eur Heart J 1995;16(12):1839-44 http://www.ncbi.nlm.nih.gov/pubmed/8682016.

585. Hedbäck B, Perk J, Wodlin P. Long-term reduction of cardiac mortality after myocardial infarction: 10-year results of a comprehensive rehabilitation programme. Eur Heart J 1993;14(6):831-5 http://www.ncbi.nlm.nih.gov/pubmed/8325313.

586. Oldridge NB, Guyatt GH, Fischer ME, et al. Cardiac rehabilitation after myocardial infarction. Combined experience of randomized clinical trials. JAMA 1988;260(7):945-50 http://www.ncbi.nlm.nih.gov/pubmed/3398199.

587. Jereczek M, Andresen D, Schroder J, et al. Prognostic value of ischemia during Holter monitoring and exercise testing after acute myocardial infarction. Am J Cardiol 1993;72(1):8-13 http://www.ncbi.nlm.nih.gov/pubmed/8517434.

588. Dubach P, Myers J, Dziekan G, et al. Effect of residential cardiac rehabilitation following bypass surgery. Observations in Switzerland. Chest 1995;108(5):1434-9 http://www.ncbi.nlm.nih.gov/pubmed/7587453.

589. Engblom E, Korpilahti K, Hamalainen H, et al. Quality of life and return to work 5 years after coronary artery bypass surgery. Long-term results of cardiac rehabilitation. J Cardiopulm Rehabil 1997;17(1):29-36 http://www.ncbi.nlm.nih.gov/pubmed/9041068.

590. Hedbäck B, Perk J, Hornblad M, et al. Cardiac rehabilitation after coronary artery bypass surgery: 10-year results on mortality, morbidity and readmissions to hospital. J Cardiovasc Risk 2001;8(3):153-8 http://www.ncbi.nlm.nih.gov/pubmed/11455847.

591. Willich SN, Muller-Nordhorn J, Kulig M, et al. Cardiac risk factors, medication, and recurrent clinical events after acute coronary disease; a prospective cohort study. Eur Heart J 2001;22(4):307-13 http://www.ncbi.nlm.nih.gov/pubmed/11161949.

592. EUROASPIRE Study Group. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997;18(10):1569-82 http://www.ncbi.nlm.nih.gov/pubmed/9347267.

593. Higgins HC, Hayes RL, McKenna KT. Rehabilitation outcomes following percutaneous coronary interventions (PCI). Patient Educ Couns 2001;43(3):219-30 http://www.ncbi.nlm.nih.gov/pubmed/11384820.

594. Hofman-Bang C, Lisspers J, Nordlander R, et al. Two-year results of a controlled study of residential rehabilitation for patients treated with percutaneous transluminal coronary angioplasty. A randomized study of a multifactorial programme. Eur Heart J 1999;20(20):1465-74 http://www.ncbi.nlm.nih.gov/pubmed/10493845.

595. Wallner S, Watzinger N, Lindschinger M, et al. Effects of intensified lifestyle modification on the need for further revascularization after coronary angioplasty. Eur J Clin Invest 1999;29(5):372-9 http://www.ncbi.nlm.nih.gov/pubmed/10354193.

596. Marchionni N, Fattirolli F, Fumagalli S, et al. Improved exercise tolerance and quality of life with cardiac rehabilitation of older patients after myocardial infarction: results of a randomized, controlled trial. Circulation 2003;107(17):2201-6 http://www.ncbi.nlm.nih.gov/pubmed/12707240.

597. Hamalainen H, Luurila OJ, Kallio V, et al. Long-term reduction in sudden deaths after a multifactorial intervention programme in patients with myocardial infarction: 10-year results of a controlled investigation. Eur Heart J 1989;10(1):55-62 http://www.ncbi.nlm.nih.gov/pubmed/2564823.

598. Marra S, Paolillo V, Spadaccini F, et al. Long-term follow-up after a controlled randomized post-myocardial infarction rehabilitation programme: effects on morbidity and mortality. Eur Heart J 1985;6(8):656-63 http://www.ncbi.nlm.nih.gov/pubmed/4054135.

599. Mayou RA, Thompson DR, Clements A, et al. Guideline-based early rehabilitation after myocardial infarction. A pragmatic randomised controlled trial. J Psychosom Res 2002;52(2):89-95 http://www.ncbi.nlm.nih.gov/pubmed/11832254.

600. Yoshida T, Yoshida K, Yamamoto C, et al. Effects of a two-week, hospitalized phase II cardiac rehabilitation program on physical capacity, lipid profiles and psychological variables in patients with acute myocardial infarction. Jpn Circ J 2001;65(2):87-93 http://www.ncbi.nlm.nih.gov/pubmed/11216831.

601. Skof E, Span M, Keber I. Secondary prevention in patients several years after myocardial infarction: comparison of an outpatient and an inpatient rehabilitation programme. J Cardiovasc Risk 2001;8(3):119-26 http://www.ncbi.nlm.nih.gov/pubmed/11455842.

602. Mayou RA, Gill D, Thompson DR, et al. Depression and anxiety as predictors of outcome after myocardial infarction. Psychosom Med 2000;62(2):212-9 http://www.ncbi.nlm.nih.gov/pubmed/10772399.

603. Simchen E, Naveh I, Zitser-Gurevich Y, et al. Is participation in cardiac rehabilitation programs associated with better quality of life and return to work after coronary artery bypass operations? The Israeli CABG Study. Isr Med Assoc J 2001;3(6):399-403 http://www.ncbi.nlm.nih.gov/pubmed/11433629.

604. National Cholesterol Education Program (NCEP). Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-97 http://www.ncbi.nlm.nih.gov/pubmed/11368702.

605. Ladwig KH, Lehmacher W, Roth R, et al. Factors which provoke post-infarction depression: results from the post-infarction late potential study (PILP). J Psychosom Res 1992;36(8):723-9 http://www.ncbi.nlm.nih.gov/pubmed/1432862.

606. Ladwig KH, Kieser M, Konig J, et al. Affective disorders and survival after acute myocardial infarction. Results from the post-infarction late potential study. Eur Heart J 1991;12(9):959-64 http://www.ncbi.nlm.nih.gov/pubmed/1936008.

607. Linden W, Stossel C, Maurice J. Psychosocial interventions for patients with coronary artery disease: a meta-analysis. Arch Intern Med 1996;156(7):745-52 http://www.ncbi.nlm.nih.gov/pubmed/8615707.

608. ENRICHD Investigators. Enhancing Recovery in Coronary Heart Disease (ENRICHD) study intervention: rationale and design. Psychosom Med 2001;63(5):747-55 http://www.ncbi.nlm.nih.gov/pubmed/11573023.

609. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003;107(1):149-58 http://www.ncbi.nlm.nih.gov/pubmed/12515758.

610. Rees K, Bennett P, West R, et al. Psychological interventions for coronary heart disease. Cochrane Database Syst Rev 2004;(2):CD002902 http://www.ncbi.nlm.nih.gov/pubmed/15106183.

611. Carlsson R. Serum cholesterol, lifestyle, working capacity and quality of life in patients with coronary artery disease. Experiences from a hospital-based secondary prevention programme. Scand Cardiovasc J Suppl 1998;50:1-20 http://www.ncbi.nlm.nih.gov/pubmed/9802147.

612. Dugmore LD, Tipson RJ, Phillips MH, et al. Changes in cardiorespiratory fitness, psychological wellbeing, quality of life, and vocational status following a 12 month cardiac exercise rehabilitation programme. Heart 1999;81(4):359-66 http://www.ncbi.nlm.nih.gov/pubmed/10092561.

613. Karoff M, Roseler S, Lorenz C, et al. Intensivierte Nachsorge (INA)--ein Verfahren zur Verbesserung der beruflichen Reintegration nach Herzinfarkt und/oder Bypassoperation. Z Kardiol 2000;89(5):423-33 http://www.ncbi.nlm.nih.gov/pubmed/10900673.

614. Boudrez H, de Backer G. Recent findings on return to work after an acute myocardial infarction or coronary artery bypass grafting. Acta Cardiol 2000;55(6):341-9 http://www.ncbi.nlm.nih.gov/pubmed/11227834.

615. Buchwalsky G, Buchwalsky R, Held K. Langzeitwirkungen der Nachsorge in einer ambulanten Herzgruppe. Eine Fall-/Kontrollstudie. Z Kardiol 2002;91(2):139-46 http://www.ncbi.nlm.nih.gov/pubmed/11963731.

616. Froom P, Cohen C, Rashcupkin J, et al. Referral to occupational medicine clinics and resumption of employment after myocardial infarction. J Occup Environ Med 1999;41(11):943-7 http://www.ncbi.nlm.nih.gov/pubmed/10570498.

617. Mark DB, Lam LC, Lee KL, et al. Identification of patients with coronary disease at high risk for loss of employment. A prospective validation study. Circulation 1992;86(5):1485-94 http://www.ncbi.nlm.nih.gov/pubmed/1423962.

618. Mittag O, Kolenda KD, Nordman KJ, et al. Return to work after myocardial infarction/coronary artery bypass grafting: patients' and physicians' initial viewpoints and outcome 12 months later. Soc Sci Med 2001;52(9):1441-50 http://www.ncbi.nlm.nih.gov/pubmed/11286367.

619. Myrtek M, Kaiser A, Rauch B, et al. Factors associated with work resumption: a 5 year follow-up with cardiac patients. Int J Cardiol 1997;59(3):291-7 http://www.ncbi.nlm.nih.gov/pubmed/9183046.

620. Noyez L, Onundu JW, Janssen DP, et al. Myocardial revascularization in patients < or = 45 years old: evaluation of cardial and functional capacity, and return to work. Cardiovasc Surg 1999;7(1):128-33 http://www.ncbi.nlm.nih.gov/pubmed/10073772.

621. Balady GJ, Ades PA, Comoss P, et al. Core components of cardiac rehabilitation/secondary prevention programs: A statement for healthcare professionals from the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation Writing Group. Circulation 2000;102(9):1069-73 http://www.ncbi.nlm.nih.gov/pubmed/10961975.

622. Dusseldorp E, van Elderen T, Maes S, et al. A meta-analysis of psychoeduational programs for coronary heart disease patients. Health Psychol 1999;18(5):506-19 http://www.ncbi.nlm.nih.gov/pubmed/10519467.

623. Kavanagh T, Mertens DJ, Hamm LF, et al. Prediction of long-term prognosis in 12 169 men referred for cardiac rehabilitation. Circulation 2002;106(6):666-71 http://www.ncbi.nlm.nih.gov/pubmed/12163425.

624. Kollner V. Welche somatischen und psychologischen Faktoren bestimmen den postoperativen Verlauf nach Herzoperationen? In: Rauch B, Held K, editors. Der schwerkranke und mulitmorbide Herzpatient - eine Herausforderung für die kardiologische Rehabilitation. Darmstadt: Steinkopff; 2001. p. 93-7.

625. McDermott MM, Schmitt B, Wallner E. Impact of medication nonadherence on coronary heart disease outcomes. A critical review. Arch Intern Med 1997;157(17):1921-9 http://www.ncbi.nlm.nih.gov/pubmed/9308504.

626. Mullen PD, Mains DA, Velez R. A meta-analysis of controlled trials of cardiac patient education. Patient Educ Couns 1992;19(2):143-62 http://www.ncbi.nlm.nih.gov/pubmed/1299819.

627. Lear SA, Ignaszewski A, Linden W, et al. The Extensive Lifestyle Management Intervention (ELMI) following cardiac rehabilitation trial. Eur Heart J 2003;24(21):1920-7 http://www.ncbi.nlm.nih.gov/pubmed/14585250.

628. Campbell NC, Thain J, Deans HG, et al. Secondary prevention clinics for coronary heart disease: randomised trial of effect on health. BMJ 1998;316(7142):1434-7 http://www.ncbi.nlm.nih.gov/pubmed/9572758.

629. Cupples ME, McKnight A. Randomised controlled trial of health promotion in general practice for patients at high cardiovascular risk. BMJ 1994;309(6960):993-6 http://www.ncbi.nlm.nih.gov/pubmed/7950723.

630. McAlister FA, Lawson FM, Teo KK, et al. Randomised trials of secondary prevention programmes in coronary heart disease: systematic review. BMJ 2001;323(7319):957-62 http://www.ncbi.nlm.nih.gov/pubmed/11679383.

631. Weingarten SR, Henning JM, Badamgarav E, et al. Interventions used in disease management programmes for patients with chronic illness-which ones work? Meta-analysis of published reports. BMJ 2002;325(7370):925 http://www.ncbi.nlm.nih.gov/pubmed/12399340.

632. Peduzzi PN, Detre KM, Chan YK, et al. Validation of a risk function to predict mortality in a VA population with coronary artery disease. Control Clin Trials 1982;3(1):47-60 http://www.ncbi.nlm.nih.gov/pubmed/7067471.

633. Spertus JA, Jones P, McDonell M, et al. Health status predicts long-term outcome in outpatients with coronary disease. Circulation 2002;106(1):43-9 http://www.ncbi.nlm.nih.gov/pubmed/12093768.

634. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction. Impact on 6-month survival. JAMA 1993;270(15):1819-25 http://www.ncbi.nlm.nih.gov/pubmed/8411525.

635. Ladwig KH, Roll G, Breithardt G, et al. Post-infarction depression and incomplete recovery 6 months after acute myocardial infarction. Lancet 1994;343(8888):20-3 http://www.ncbi.nlm.nih.gov/pubmed/7905043.

636. Ruberman W, Weinblatt E, Goldberg JD, et al. Psychosocial influences on mortality after myocardial infarction. N Engl J Med 1984;311(9):552-9 http://www.ncbi.nlm.nih.gov/pubmed/6749228.

637. Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002;288(6):701-9 http://www.ncbi.nlm.nih.gov/pubmed/12169073.

638. Ketola E, Sipila R, Mäkelä M. Effectiveness of individual lifestyle interventions in reducing cardiovascular disease and risk factors. Ann Med 2000;32(4):239-51 http://www.ncbi.nlm.nih.gov/pubmed/10852140.

639. Hill DR, Kelleher K, Shumaker SA. Psychosocial interventions in adult patients with coronary heart disease and cancer. A literature review. Gen Hosp Psychiatry 1992;14(6 Suppl):28S-42S http://www.ncbi.nlm.nih.gov/pubmed/1340846.

640. Maynard C, Althouse R, Olsufka M, et al. Early versus late hospital arrival for acute myocardial infarction in the western Washington thrombolytic therapy trials. Am J Cardiol 1989;63(18):1296-300 http://www.ncbi.nlm.nih.gov/pubmed/2499171.

641. GISSI-Avoidable Delay Study Group. Epidemiology of avoidable delay in the care of patients with acute myocardial infarction in Italy. A GISSI-generated study. Arch Intern Med 1995;155(14):1481-8 http://www.ncbi.nlm.nih.gov/pubmed/7605149.

642. Moher M, Yudkin P, Wright L, et al. Cluster randomised controlled trial to compare three methods of promoting secondary prevention of coronary heart disease in primary care. BMJ 2001;322(7298):1338 http://www.ncbi.nlm.nih.gov/pubmed/11387182.

643. Flanagan DE, Cox P, Paine D, et al. Secondary prevention of coronary heart disease in primary care: a healthy heart initiative. Q J Med 1999;92(5):245-50 http://www.ncbi.nlm.nih.gov/pubmed/10615479.

644. Jenkins CD, Stanton BA, Klein MD, et al. Correlates of angina pectoris among men awaiting coronary by-pass surgery. Psychosom Med 1983;45(2):141-53 http://www.ncbi.nlm.nih.gov/pubmed/6602995.

645. Main CJ, Spanswick CC, Watson P. The nature of disability. In: Main CJ, Spanswick CC, editors. Pain management. An interdisciplinary approach. Edinburgh: Churchill Livingstone; 2000. p. 98-106.

646. Lewin RJ. Improving quality of life in patients with angina. Heart 1999;82(6):654-5 http://www.ncbi.nlm.nih.gov/pubmed/10573485.

647. Kouyanou K, Pither CE, Wessely S. Iatrogenic factors and chronic pain. Psychosom Med 1997;59(6):597-604 http://www.ncbi.nlm.nih.gov/pubmed/9407578.

648. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1995;91(4):999-1005 http://www.ncbi.nlm.nih.gov/pubmed/7531624.

649. Allison TG, Williams DE, Miller TD, et al. Medical and economic costs of psychologic distress in patients with coronary artery disease. Mayo Clin Proc 1995;70(8):734-42 http://www.ncbi.nlm.nih.gov/pubmed/7630210.

650. Barefoot JC, Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation 1996;93(11):1976-80 http://www.ncbi.nlm.nih.gov/pubmed/8640971.

651. Frasure-Smith N, Lesperance F, Gravel G, et al. Depression and health-care costs during the first year following myocardial infarction. J Psychosom Res 2000;48(4-5):471-8 http://www.ncbi.nlm.nih.gov/pubmed/10880668.

652. Frasure-Smith N, Lesperance F, Prince RH, et al. Randomised trial of home-based psychosocial nursing intervention for patients recovering from myocardial infarction. Lancet 1997;350(9076):473-9 http://www.ncbi.nlm.nih.gov/pubmed/9274583.

653. Barlow J, Wright C, Sheasby J, et al. Self-management approaches for people with chronic conditions: a review. Patient Educ Couns 2002;48(2):177-87 http://www.ncbi.nlm.nih.gov/pubmed/12401421.

654. Lewin RJ, Furze G, Robinson J, et al. A randomised controlled trial of a self-management plan for patients with newly diagnosed angina. Br J Gen Pract 2002;52(476):194-201 http://www.ncbi.nlm.nih.gov/pubmed/12030661.

655. Frijling BD, Lobo CM, Hulscher ME, et al. Provision of information and advice in cardiovascular care: clinical performance of general practitioners. Patient Educ Couns 2002;48(2):131-7 http://www.ncbi.nlm.nih.gov/pubmed/12401416.

656. Khunti K, Sorrie R, Jennings S, et al. Improving aspirin prophylaxis after myocardial infarction in primary care: collaboration in multipractice audit between primary care audit group and health authority. BMJ 1999;319(7205):297 http://www.ncbi.nlm.nih.gov/pubmed/10426745.

657. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001;357(9261):995-1001 http://www.ncbi.nlm.nih.gov/pubmed/11293642.

658. Gemeinsamer Bundesausschuss (G-BA). Empfehlungen des Koordinierungsausschusses gemäß § 137 f Absatz 2 SGB V "Anforderungen" an die Ausgestaltung von strukturierten Behandlungsprogrammen für Patienten mit Koronarer Herzkrankheit. Siegburg, 31.03.2003. 2003 [cited: 2006 Jun 09]. Available from: http://www.g-ba.de/cms/front_content.php?idcat=85&start=10

659. Herold G. Innere Medizin. Unter Berücksichtigung des Gegenstandskataloges für die ärztliche Prüfung. Mit ICD 10-Schlüssel im Text und Stichwortverzeichnis. Eine vorlesungsorientierte Darstellung. Köln: Herold; 2010.

660. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993;329(10):673-82 http://www.ncbi.nlm.nih.gov/pubmed/8204123.

661. Pschyrembel W, (ed.). Pschyrembel. Klinisches Wörterbuch. 260th ed. Berlin: De Gruyter; 2004.

662. Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004;364(9437):849-57 http://www.ncbi.nlm.nih.gov/pubmed/15351192.

663. Goldberg RJ, Currie K, White K, et al. Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (the Global Registry of Acute Coronary Events [GRACE]). Am J Cardiol 2004;93(3):288-93 http://www.ncbi.nlm.nih.gov/pubmed/14759376.

664. Ruygrok PN, de Jaegere PT, van Domburg RT, et al. Clinical outcome 10 years after attempted percutaneous transluminal coronary angioplasty in 856 patients. Journal of the American College of Cardiology 1996;27(7):1669-77 http://www.ncbi.nlm.nih.gov/pubmed/8636552.

665. Brorsson B, Bernstein SJ, Brook RH, et al. Quality of life of patients with chronic stable angina before and four years after coronary revascularisation compared with a normal population. Heart 2002;87(2):140-5 http://www.ncbi.nlm.nih.gov/pubmed/11796552.

666. Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004;291(22):2727-33 http://www.ncbi.nlm.nih.gov/pubmed/15187054.

667. Emond M, Mock MB, Davis KB, et al. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation 1994;90(6):2645-57 http://www.ncbi.nlm.nih.gov/pubmed/7994804.

668. Henderson RA, Pocock SJ, Clayton TC, et al. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. Journal of the American College of Cardiology 2003;42(7):1161-70 http://www.ncbi.nlm.nih.gov/pubmed/14522473.

669. Sanz G, Castaner A, Betriu A, et al. Determinants of prognosis in survivors of myocardial infarction: a prospective clinical angiographic study. N Engl J Med 1982;306(18):1065-70 http://www.ncbi.nlm.nih.gov/pubmed/7070402.

670. The Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med 1983;309(6):331-6 http://www.ncbi.nlm.nih.gov/pubmed/6866068.

671. Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999;159(22):2661-7 http://www.ncbi.nlm.nih.gov/pubmed/10597756.

672. Malmberg K, Norhammar A, Wedel H, et al. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999;99(20):2626-32 http://www.ncbi.nlm.nih.gov/pubmed/10338454.

673. Tu JV, Austin PC, Walld R, et al. Development and validation of the Ontario acute myocardial infarction mortality prediction rules. Journal of the American College of Cardiology 2001;37(4):992-7 http://www.ncbi.nlm.nih.gov/pubmed/11263626.

674. Detre K, Peduzzi P, Murphy M, et al. Effect of bypass surgery on survival in patients in low- and high-risk subgroups delineated by the use of simple clinical variables. Circulation 1981;63(6):1329-38 http://www.ncbi.nlm.nih.gov/pubmed/6971716.

675. Daly C, Norrie J, Murdoch DL, et al. The value of routine non-invasive tests to predict clinical outcome in stable angina. Eur Heart J 2003;24(6):532-40 http://www.ncbi.nlm.nih.gov/pubmed/12643886.

676. Dargie HJ, Ford I, Fox KM. Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group. Eur Heart J 1996;17(1):104-12 http://www.ncbi.nlm.nih.gov/pubmed/8682116.

677. Pepine CJ, Cohn PF, Deedwania PC, et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST). Circulation 1994;90(2):762-8 http://www.ncbi.nlm.nih.gov/pubmed/8044945.

678. Rehnqvist N, Hjemdahl P, Billing E, et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996;17(1):76-81 http://www.ncbi.nlm.nih.gov/pubmed/8682134.

zurück nach oben


Zurück zum Anhang

zuletzt verändert: 15.06.2017 13:44